ATE482965T1 - 6-modifizierte bicyclische nukleinsäureanaloga - Google Patents

6-modifizierte bicyclische nukleinsäureanaloga

Info

Publication number: ATE482965T1
Authority: AT; Austria
Prior art keywords: nucleic acid; acid analogues; bicyclic nucleic; modified bicyclic; nucleoside analogs
Prior art date: 2006-01-27

Application number

AT07762892T

Other languages

English (en)

Inventor

Eric Swayze

Punit Seth

Original Assignee

Isis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-01-27

Filing date

2007-01-27

Publication date

2010-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38328111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE482965(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-01-27 Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc

2010-10-15 Application granted granted Critical

2010-10-15 Publication of ATE482965T1 publication Critical patent/ATE482965T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT07762892T 2006-01-27 2007-01-27 6-modifizierte bicyclische nukleinsäureanaloga ATE482965T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US76272206P	2006-01-27	2006-01-27
US80566006P	2006-06-23	2006-06-23
PCT/US2007/061183 WO2007090071A2 (en)	2006-01-27	2007-01-27	6-modified bicyclic nucleic acid analogs

Publications (1)

Publication Number	Publication Date
ATE482965T1 true ATE482965T1 (de)	2010-10-15

Family

ID=38328111

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07762892T ATE482965T1 (de)	2006-01-27	2007-01-27	6-modifizierte bicyclische nukleinsäureanaloga

Country Status (13)

Country	Link
US (3)	US7399845B2 (de)
EP (3)	EP2332951A3 (de)
JP (2)	JP5342881B2 (de)
KR (2)	KR20130042043A (de)
CN (2)	CN102766630B (de)
AT (1)	ATE482965T1 (de)
AU (1)	AU2007211080B9 (de)
CA (1)	CA2640171C (de)
DE (1)	DE602007009487D1 (de)
DK (2)	DK1984381T3 (de)
ES (1)	ES2516815T3 (de)
PL (2)	PL1984381T3 (de)
WO (1)	WO2007090071A2 (de)

Families Citing this family (750)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7511131B2 (en)	2002-11-13	2009-03-31	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
CA2994089A1 (en) *	2002-11-18	2004-06-03	Roche Innovation Center Copenhagen A/S	Antisense gapmer oligonucleotides
US20050287558A1 (en)	2004-05-05	2005-12-29	Crooke Rosanne M	SNPs of apolipoprotein B and modulation of their expression
DE102005042073B4 (de) *	2005-08-31	2010-11-11	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Faserlaser
EP1976567B1 (de)	2005-12-28	2020-05-13	The Scripps Research Institute	Natürliche antisense- und nicht-kodierende rna-transkripte als arzneitargets
CA2640171C (en) *	2006-01-27	2014-10-28	Isis Pharmaceuticals, Inc.	6-modified bicyclic nucleic acid analogs
WO2007136989A2 (en)	2006-05-05	2007-11-29	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating expression of dgat2
EP2527442A3 (de) *	2006-05-05	2013-03-06	Isis Pharmaceuticals, Inc.	Verbindungen und Verfahren zur Modulation von Genexpression
US7666854B2 (en) *	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
CA2651453C (en) *	2006-05-11	2014-10-14	Isis Pharmaceuticals, Inc.	5'-modified bicyclic nucleic acid analogs
EP3916095A1 (de)	2006-10-18	2021-12-01	Ionis Pharmaceuticals, Inc.	Antisense-verbindungen
JP2010510807A (ja)	2006-11-27	2010-04-08	アイシスファーマシューティカルズ，インコーポレーテッド	高コレステロール血症を治療するための方法
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
BRPI0809320A2 (pt)	2007-03-24	2014-09-23	Genzyme Corp	Método
ES2376507T5 (es) *	2007-07-05	2015-08-31	Isis Pharmaceuticals, Inc.	Análogos de ácidos nucleicos bicíclicos 6-disustituidos
CN101821277B (zh)	2007-08-15	2014-05-07	Isis制药公司	四氢吡喃核酸类似物
EP2220230A2 (de)	2007-11-09	2010-08-25	Isis Pharmaceuticals, Inc.	Modulation der expression von faktor 9
EP2227545A2 (de)	2007-11-09	2010-09-15	Isis Pharmaceuticals, Inc.	Modulation der expression von faktor 7
US8530640B2 (en) *	2008-02-07	2013-09-10	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexitol nucleic acid analogs
US8426378B2 (en)	2008-03-21	2013-04-23	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucelosides and methods for their use
US9290534B2 (en) *	2008-04-04	2016-03-22	Ionis Pharmaceuticals, Inc.	Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
EP2274423A2 (de)	2008-04-04	2011-01-19	Isis Pharmaceuticals, Inc.	Bicyclische nukleoside umfassende oligomere verbindungen mit verringerter toxizität
US8541387B2 (en) *	2008-05-22	2013-09-24	Isis Pharmaceuticals, Inc.	Modulation of SMRT expression
EP2323667A4 (de) *	2008-08-07	2012-07-25	Isis Pharmaceuticals Inc	Modulierung der transthyretin-expression durch behandlung von zns-erkrankungen
WO2010019270A1 (en) *	2008-08-14	2010-02-18	Isis Pharmaceuticals, Inc.	Modulation of prion expression
US8946172B2 (en) *	2008-08-25	2015-02-03	Excaliard Pharmaceuticals, Inc.	Method for reducing scarring during wound healing using antisense compounds directed to CTGF
AU2009275387B2 (en)	2008-08-25	2010-07-08	Excaliard Pharmaceuticals, Inc.	Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
WO2010027831A1 (en)	2008-08-25	2010-03-11	Excaliard Pharmaceuticals, Inc.	Method for reducing scarring during wound healing using antisense compounds directed to ctgf
DK2361256T3 (da)	2008-09-24	2013-07-01	Isis Pharmaceuticals Inc	Cyclohexenyl-nukleinsyreanaloger
DK2356129T3 (da) *	2008-09-24	2013-05-13	Isis Pharmaceuticals Inc	Substituerede alpha-L-bicykliske nukleosider
CN102239260B (zh)	2008-10-03	2017-04-12	库尔纳公司	通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
CN103820450B (zh)	2008-10-15	2018-08-21	Ionis制药公司	因子11表达的调节
WO2010048585A2 (en)	2008-10-24	2010-04-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
RU2572826C2 (ru)	2008-12-02	2016-01-20	Чиралджен, Лтд.	Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
RU2618688C2 (ru)	2008-12-04	2017-05-10	КьюРНА,Инк.,US	Лечение связанных с геном-супрессором опухолей заболеваний посредством ингибирования природного транскрипта в антисмысловой ориентации относительно этого гена
EP2370581B1 (de)	2008-12-04	2016-08-03	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem vaskulären endothelialen wachstumsfaktor (vegf) mittels hemmung des natürlichen antisense-transkripts gegen vegf
CA2745329C (en)	2008-12-04	2022-07-12	Opko Curna, Llc	Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
WO2010076248A1 (en)	2008-12-31	2010-07-08	Santaris Pharma A/S	Use of lna apob antisense oligomers for the treatment of acute coronary syndromes
WO2010090830A1 (en) *	2009-01-20	2010-08-12	Isis Pharmaceuticals, Inc.	Modulation of sirt1 expression
US20120021515A1 (en)	2009-02-06	2012-01-26	Swayze Eric E	Oligomeric compounds and methods
WO2010090969A1 (en)	2009-02-06	2010-08-12	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
EP2396038B1 (de)	2009-02-12	2015-10-21	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem brain-derived neurotrophen faktor (bdnf) mittels hemmung des natürlichen antisense-transkripts gegen bdnf
EP2408796B1 (de)	2009-03-16	2020-04-22	Ionis Pharmaceuticals, Inc.	Targeting Apolipoprotein B für die Reduktion von Apolipoprotein C-III
ES2656290T3 (es)	2009-03-16	2018-02-26	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor nuclear (derivado de eritroide 2) similar al 2 (NRF2) mediante inhibición del transcrito antisentido natural a NRF2
CA2755404C (en)	2009-03-17	2020-03-24	Joseph Collard	Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
WO2010120511A2 (en)	2009-03-31	2010-10-21	Altair Therapeutics, Inc.	Method of treating respiratory disorders
WO2010129746A2 (en)	2009-05-06	2010-11-11	Curna, Inc.	Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
EP2427553A4 (de)	2009-05-06	2012-11-07	Opko Curna Llc	Behandlung von lipidtransport- und stoffwechselgenbedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein lipidtransport- und stoffwechselgen
JP5931720B2 (ja)	2009-05-08	2016-06-08	クルナ・インコーポレーテッド	Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
JP5922017B2 (ja)	2009-05-18	2016-05-24	クルナ・インコーポレーテッド	リプログラミング因子に対する天然アンチセンス転写物の抑制によるリプログラミング因子関連疾患の治療
US8895527B2 (en)	2009-05-22	2014-11-25	Curna, Inc.	Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3
US8791085B2 (en)	2009-05-28	2014-07-29	Curna, Inc.	Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
WO2010142805A1 (en)	2009-06-12	2010-12-16	Santaris Pharma A/S	New potent anti apob antisense compounds
CN102695797B (zh)	2009-06-16	2018-05-25	库尔纳公司	通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病
CA2765509C (en)	2009-06-16	2021-08-17	Joseph Collard	Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
PT3305302T (pt)	2009-06-17	2018-12-14	Biogen Ma Inc	Composições e métodos de modulação de excisões de smn2 em um sujeito
US20120108800A1 (en)	2009-06-23	2012-05-03	Shumpei Murata	Method for synthesizing nucleic acid
CN102597238B (zh)	2009-06-24	2016-06-29	库尔纳公司	通过抑制针对肿瘤坏死因子受体2(tnfr2)的天然反义转录物来治疗tnfr2相关的疾病
EP2446037B1 (de)	2009-06-26	2016-04-20	CuRNA, Inc.	Behandlung von krankheiten im zusammenhang mit dem down-syndrom-gen durch hemmung des natürlichen antisense-transkripts zu einem down-syndrom-gen
SG10201403841QA (en)	2009-07-06	2014-09-26	Ontorii Inc	Novel nucleic acid prodrugs and methods of use thereof
US8563528B2 (en)	2009-07-21	2013-10-22	Santaris Pharma A/S	Antisense oligomers targeting PCSK9
JP2013500017A (ja)	2009-07-24	2013-01-07	カッパーアールエヌエー，インコーポレイテッド	サ−チュイン（ｓｉｒｔ）への天然アンチセンス転写物の阻止によるサ−チュイン（ｓｉｒｔ）関連疾患の治療
KR101802536B1 (ko)	2009-08-05	2017-11-28	큐알엔에이, 인크.	인슐린 유전자 (ｉｎｓ)에 대한 자연 안티센스 전사체의 저해에 의한 인슐린 유전자 (ｉｎｓ) 관련된 질환의 치료
EP2462153B1 (de)	2009-08-06	2015-07-29	Isis Pharmaceuticals, Inc.	Bicyclische cyclohexosenukleinsäureanaloga
KR101827015B1 (ko)	2009-08-11	2018-02-07	큐알엔에이, 인크.	아디포넥틴(ａｄｉｐｏｑ)에 대한 천연 안티센스 전사체의 억제에 의한 아디포넥틴(ａｄｉｐｏｑ) 관련된 질환의 치료
EP2467482A4 (de)	2009-08-21	2013-12-11	Curna Inc	Behandlung von chip (c-terminus des hsp70-interagierenden proteins)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen chip
US9023822B2 (en)	2009-08-25	2015-05-05	Curna, Inc.	Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
WO2011032045A1 (en)	2009-09-11	2011-03-17	Isis Pharmaceuticals, Inc.	Modulation of huntingtin expression
CN102791861B (zh)	2009-09-25	2018-08-07	库尔纳公司	通过调节聚丝蛋白(flg)的表达和活性而治疗flg相关疾病
US9364495B2 (en)	2009-10-20	2016-06-14	Roche Innovation Center Copenhagen A/S	Oral delivery of therapeutically effective LNA oligonucleotides
WO2011054811A1 (en)	2009-11-03	2011-05-12	Santaris Pharma A/S	Rna antagonists targeting hsp27 combination therapy
CA2782366A1 (en)	2009-12-16	2011-07-14	Opko Curna, Llc	Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
EP2516648B1 (de)	2009-12-23	2017-11-08	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem häpatozyten-wachstumsfaktor (hgf) mittels hemmung des natürlichen antisense-transkripts gegen hgf
EP2515947B1 (de)	2009-12-23	2021-10-06	CuRNA, Inc.	Behandlung von durch das uncoupling protein 2 (ucp2) bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts für ucp2
RU2615450C2 (ru)	2009-12-29	2017-04-04	Курна, Инк.	Лечение заболеваний, связанных с ядерным респираторным фактором 1(nrf1), путем ингибирования природного антисмыслового транскрипта к nrf1
US8962585B2 (en)	2009-12-29	2015-02-24	Curna, Inc.	Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
WO2011082281A2 (en)	2009-12-31	2011-07-07	Curna, Inc.	Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
JP5886757B2 (ja)	2010-01-04	2016-03-16	カッパーアールエヌエー，インコーポレイテッド	インターフェロン調節因子８（ｉｒｆ８）に対する天然アンチセンス転写物の阻害によるインターフェロン調節因子８（ｉｒｆ８）関連疾患の治療
EP2521785B1 (de)	2010-01-06	2022-03-09	CuRNA, Inc.	Inhibition des natürlichen antisense-transkripts des pankreasentwicklungsgens zur verwendung in der behandlung von pankreatischen entwicklungsgenbezogenen krankheiten
CA2786071C (en)	2010-01-08	2021-01-12	Isis Pharmaceuticals, Inc.	Modulation of angiopoietin-like 3 expression
CA2786535C (en)	2010-01-11	2019-03-26	Curna, Inc.	Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
WO2011085102A1 (en)	2010-01-11	2011-07-14	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
US20110172296A1 (en) *	2010-01-12	2011-07-14	Bennett C Frank	Modulation of transforming growth factor-beta 1 expression
US8946182B2 (en)	2010-01-25	2015-02-03	Curna, Inc.	Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
US9006198B2 (en)	2010-02-08	2015-04-14	Isis Pharmaceuticals, Inc.	Selective reduction of allelic variants
ES2733708T3 (es)	2010-02-08	2019-12-02	Ionis Pharmaceuticals Inc	Reducción selectiva de variantes alélicas
JP5976548B2 (ja)	2010-02-22	2016-08-23	カッパーアールエヌエー，インコーポレイテッド	Ｐｙｃｒ１に対する天然アンチセンス転写物の阻害によるピロリン−５−カルボン酸レダクターゼ１（ｐｙｃｒ１）関連疾患の治療
US20110213011A1 (en) *	2010-02-26	2011-09-01	Dean Nicholas M	Modulation of smad3 expression
WO2011115817A1 (en)	2010-03-16	2011-09-22	Isis Pharmaceuticals, Inc.	Methods of preparing 2'-o-substituted purine nucleosides
WO2011115818A1 (en)	2010-03-17	2011-09-22	Isis Pharmaceuticals, Inc.	5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
US8980856B2 (en)	2010-04-02	2015-03-17	Curna, Inc.	Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
JP2013523162A (ja)	2010-04-06	2013-06-17	アルナイラムファーマシューティカルズ，インコーポレイテッド	Ｃｄ２７４／ｐｄ−ｌ１遺伝子の発現を阻害するための組成物および方法
US9044494B2 (en)	2010-04-09	2015-06-02	Curna, Inc.	Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
US9127033B2 (en)	2010-04-28	2015-09-08	Isis Pharmaceuticals, Inc.	5′ modified nucleosides and oligomeric compounds prepared therefrom
WO2011139702A2 (en)	2010-04-28	2011-11-10	Isis Pharmaceuticals, Inc.	Modified nucleosides and oligomeric compounds prepared therefrom
US9156873B2 (en)	2010-04-28	2015-10-13	Isis Pharmaceuticals, Inc.	Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
CA2797792C (en)	2010-04-29	2018-02-27	Isis Pharmaceuticals, Inc.	Modulation of transthyretin expression
US20130156845A1 (en)	2010-04-29	2013-06-20	Alnylam Pharmaceuticals, Inc.	Lipid formulated single stranded rna
EP2957636B1 (de)	2010-05-03	2020-04-01	CuRNA, Inc.	Behandlung von sirtuin 3 (sirt3)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt3
TWI531370B (zh)	2010-05-14	2016-05-01	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
CA2799596C (en)	2010-05-26	2020-09-22	Curna, Inc.	Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
WO2011150005A2 (en)	2010-05-26	2011-12-01	Opko Curna Llc	Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
US9944671B2 (en)	2010-06-02	2018-04-17	Alnylam Pharmaceuticals, Inc.	Compositions and methods directed to treating liver fibrosis
WO2011156278A1 (en)	2010-06-07	2011-12-15	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011156202A1 (en)	2010-06-08	2011-12-15	Isis Pharmaceuticals, Inc.	Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US9518259B2 (en)	2010-06-15	2016-12-13	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating interaction between proteins and target nucleic acids
DK2585596T3 (da)	2010-06-23	2021-04-06	Curna Inc	Behandling af spændingsreguleret natriumkanal-alpha-underenhed (scna)-relaterede sygdomme ved inhibering af naturligt antisense-transkript til scna
WO2012007477A1 (en)	2010-07-12	2012-01-19	Santaris Pharma A/S	Anti hcv oligomers
NO2593547T3 (de)	2010-07-14	2018-04-14
KR101900770B1 (ko)	2010-07-19	2018-09-20	아이오니스 파마수티컬즈, 인코포레이티드	근육긴장성 이영양증-단백질 키나제(dmpk) 발현의 조절 방법
US9081737B2 (en)	2010-08-02	2015-07-14	Integrated Dna Technologies, Inc.	Methods for predicting stability and melting temperatures of nucleic acid duplexes
WO2012034942A1 (en)	2010-09-13	2012-03-22	Santaris Pharma A/S	Compounds for the modulation of aurora kinase b expression
EP2620428B1 (de)	2010-09-24	2019-05-22	Wave Life Sciences Ltd.	Asymmetrische hilfsgruppe
EP2625274B1 (de)	2010-10-06	2017-07-19	CuRNA, Inc.	Behandlung sialidase-4-(neu4)-vermittelter erkrankungen durch hemmung des natürlichen antisense-transkripts gegen neu4
US8648053B2 (en)	2010-10-20	2014-02-11	Rosalind Franklin University Of Medicine And Science	Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
KR101865433B1 (ko)	2010-10-22	2018-07-13	큐알엔에이, 인크.	알파-l 이두로니다아제 (idua)에 대한 자연 안티센스 전사체의 저해에 의한 idua 관련된 질환의 치료
WO2012064758A2 (en)	2010-11-08	2012-05-18	Isis Pharmaceuticals, Inc.	Methods for modulating factor 12 expression
AU2011329777B2 (en)	2010-11-17	2016-06-09	Ionis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
US10000752B2 (en)	2010-11-18	2018-06-19	Curna, Inc.	Antagonat compositions and methods of use
WO2012066093A1 (en)	2010-11-19	2012-05-24	Santaris Pharma A/S	Compounds for the modulation of pdz-binding kinase (pbk) expression
WO2012066092A1 (en)	2010-11-19	2012-05-24	Santaris Pharma A/S	Compounds for the modulation of aurora kinase a expression
CA2818824A1 (en)	2010-11-23	2012-05-31	Joseph Collard	Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
EP2649182A4 (de)	2010-12-10	2015-05-06	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur erhöhung einer erythropoietin (epo)-herstellung
WO2012079046A2 (en)	2010-12-10	2012-06-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
HUE044178T4 (hu)	2011-02-02	2019-10-28	Excaliard Pharmaceuticals Inc	Kötõszöveti növekedési faktort (CTGF) célzó antiszensz vegyületek keloidok vagy hipertrófiás hegek kezelési eljárásban történõ alkalmazásra
US10017764B2 (en)	2011-02-08	2018-07-10	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2012110457A2 (en)	2011-02-14	2012-08-23	Santaris Pharma A/S	Compounds for the modulation of osteopontin expression
SG193923A1 (en)	2011-03-29	2013-11-29	Alnylam Pharmaceuticals Inc	Compositions and methods for inhibiting expression of tmprss6 gene
KR102050469B1 (ko)	2011-04-01	2019-12-02	아이오니스 파마수티컬즈, 인코포레이티드	전사 신호 전달 인자 및 활성 인자 3(ｓｔａｔ３) 발현 조절
US8658783B2 (en)	2011-04-13	2014-02-25	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
WO2012143427A1 (en)	2011-04-19	2012-10-26	Santaris Pharma A/S	Anti polyomavirus compounds
AU2012245243B2 (en)	2011-04-21	2015-03-12	Glaxo Group Limited	Modulation of Hepatitis B virus (HBV) expression
PT2702155T (pt)	2011-04-25	2017-04-03	Regulus Therapeutics Inc	Compostos de microrna e métodos para modular a atividade de mir-21
AU2012249324B2 (en)	2011-04-27	2016-10-06	Ionis Pharmaceuticals, Inc.	Modulation of apolipoprotein CIII (ApoCIII) expression
WO2012151324A1 (en)	2011-05-02	2012-11-08	Isis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with usher syndrome
WO2012170347A1 (en)	2011-06-09	2012-12-13	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2012170771A1 (en)	2011-06-09	2012-12-13	Curna, Inc.	Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
US9187749B2 (en)	2011-06-10	2015-11-17	Isis Pharmaceuticals, Inc.	Methods for modulating factor 12 expression
EP2717923B1 (de)	2011-06-10	2017-09-27	Ionis Pharmaceuticals, Inc.	Verfahren zur modulierung der kallikrein (klkb1)-expression
CN103597074A (zh)	2011-06-16	2014-02-19	Isis制药公司	成纤维细胞生长因子受体4表达的反义调节
EP3656860B1 (de)	2011-06-21	2022-04-20	Alnylam Pharmaceuticals, Inc.	Angiopoietin-like-3 (angptl3)-irna-zusammensetzungen und verfahren zur verwendung davon
EP3366312A1 (de)	2011-06-23	2018-08-29	Alnylam Pharmaceuticals, Inc.	Serpina 1 sirnas: materialzusammensetzungen und verfahren zur behandlung
KR20140051271A (ko)	2011-06-23	2014-04-30	스텔라 에이피에스	Hcv 조합 치료
EP2726153B1 (de)	2011-06-29	2018-03-28	Ionis Pharmaceuticals, Inc.	Verfahren zur modulierung der kallikrein (klkb1)-expression
KR20140058536A (ko)	2011-06-30	2014-05-14	스텔라 에이피에스	Hcv 조합 치료
WO2013000855A1 (en)	2011-06-30	2013-01-03	Santaris Pharma A/S	Hcv combination therapy
US9605019B2 (en)	2011-07-19	2017-03-28	Wave Life Sciences Ltd.	Methods for the synthesis of functionalized nucleic acids
US20140328811A1 (en)	2011-08-01	2014-11-06	Alnylam Pharmaceuticals, Inc.	Method for improving the success rate of hematopoietic stem cell transplants
ES2635866T5 (es)	2011-08-11	2021-04-05	Ionis Pharmaceuticals Inc	Enlace modificado de compuestos oligomericos y usos de los mismos
US10023861B2 (en)	2011-08-29	2018-07-17	Ionis Pharmaceuticals, Inc.	Oligomer-conjugate complexes and their use
EP2751269B1 (de)	2011-08-29	2016-03-23	Ionis Pharmaceuticals, Inc.	Verfahren und verbindungen für erkrankungen im zusammenhang mit repeat-expansion
CN103874486A (zh)	2011-09-06	2014-06-18	库尔纳公司	用小分子治疗与电压门控钠通道的α亚基(SCNxA)相关的疾病
US9580708B2 (en)	2011-09-14	2017-02-28	Rana Therapeutics, Inc.	Multimeric oligonucleotides compounds
IN2014CN02736A (de)	2011-09-20	2015-07-03	Isis Phamaceuticals Inc
US8901098B2 (en)	2011-10-25	2014-12-02	Isis Pharmaceuticals, Inc.	Antisense modulation of GCCR expression
WO2013067050A1 (en)	2011-10-31	2013-05-10	University Of Utah Research Foundation	Genetic alterations in glioblastoma
AU2012334214A1 (en)	2011-11-07	2014-05-22	Roche Innovation Center Copenhagen A/S	Prognostic method for checking efficacy of micro RNA-122 inhibitors in HCV+ patients
WO2013068348A1 (en)	2011-11-07	2013-05-16	Santaris Pharma A/S	Lna oligomers for improvement in hepatic function
WO2013070786A1 (en)	2011-11-07	2013-05-16	Isis Pharmaceuticals, Inc.	Modulation of tmprss6 expression
EP2776563A1 (de)	2011-11-11	2014-09-17	Santaris Pharma A/S	Verbindungen zur modulation einer smn2-spleissung
US9243291B1 (en)	2011-12-01	2016-01-26	Isis Pharmaceuticals, Inc.	Methods of predicting toxicity
EP2790736B1 (de)	2011-12-12	2018-01-31	Oncoimmunin, Inc.	In-vivo-verabreichung von oligonucleotiden
AU2012352180A1 (en)	2011-12-16	2014-07-31	Moderna Therapeutics, Inc.	Modified nucleoside, nucleotide, and nucleic acid compositions
DK2794880T3 (en)	2011-12-22	2018-07-23	Ionis Pharmaceuticals Inc	METHOD OF MODULATING METASTASE-ASSOCIATED-IN-LONG-ADENOCARCINOM TRANSCRIPT-1- (MALATE-1) EXPRESSION
EP2802674B1 (de)	2012-01-11	2020-12-16	Ionis Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur modulation der ikbkap-aufspaltung
WO2013119602A1 (en)	2012-02-06	2013-08-15	President And Fellows Of Harvard College	Arrdc1-mediated microvesicles (armms) and uses thereof
EP2812342B1 (de)	2012-02-08	2017-11-15	Ionis Pharmaceuticals, Inc.	Modulation von rna durch wiederholtes targeting
JP2015511494A (ja)	2012-03-15	2015-04-20	キュアナ，インク．	脳由来神経栄養因子（ｂｄｎｆ）に対する天然アンチセンス転写物の阻害によるｂｄｎｆ関連の疾患の処置
WO2013142514A1 (en)	2012-03-19	2013-09-26	Isis Pharmaceuticals, Inc.	Methods and compositions for modulating alpha-1-antitrypsin expression
EP2831231A1 (de)	2012-03-30	2015-02-04	Isis Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur modulation der tau-expression zur verringerung von anfällen und modifizierung eines neurodegenerativen syndroms
JP2015518705A (ja)	2012-04-02	2015-07-06	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド
WO2013151672A2 (en)	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of oncology-related proteins and peptides
WO2013154799A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
WO2013154798A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleic acid analogs
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
EP3336189A1 (de)	2012-04-20	2018-06-20	Ionis Pharmaceuticals, Inc.	Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
IN2014DN09134A (de)	2012-04-25	2015-05-22	Regulus Therapeutics Inc
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
US20150133362A1 (en)	2012-05-16	2015-05-14	Rana Therapeutics, Inc.	Compositions and methods for modulating gene expression
AU2013262649A1 (en)	2012-05-16	2015-01-22	Rana Therapeutics, Inc.	Compositions and methods for modulating smn gene family expression
US20160002624A1 (en)	2012-05-17	2016-01-07	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide compositions
US9574193B2 (en)	2012-05-17	2017-02-21	Ionis Pharmaceuticals, Inc.	Methods and compositions for modulating apolipoprotein (a) expression
WO2013177248A2 (en)	2012-05-22	2013-11-28	Isis Pharmaceuticals, Inc.	Modulation of enhancer rna mediated gene expression
AU2013266196A1 (en)	2012-05-24	2014-11-20	Ionis Pharmaceuticals, Inc.	Methods and compositions for modulating apolipoprotein(a) expression
WO2013181665A1 (en)	2012-06-01	2013-12-05	Isis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with fibronectin
WO2013181666A2 (en)	2012-06-01	2013-12-05	Isis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with fibronectin
DK3461895T3 (da)	2012-06-25	2020-07-20	Ionis Pharmaceuticals Inc	Modulation af ube3a-ats-ekspression
BR112015000784A8 (pt)	2012-07-13	2018-04-03	Wave Life Sciences Japan	Grupo auxiliar assimétrico
MX356830B (es)	2012-07-13	2018-06-15	Shin Nippon Biomedical Laboratories Ltd	Adyuvante de acido nucleico quiral.
CN112007045A (zh)	2012-07-13	2020-12-01	波涛生命科学有限公司	手性控制
ES2773489T3 (es)	2012-07-27	2020-07-13	Ionis Pharmaceuticals Inc	Modulación de enfermedades relacionadas con el sistema renina-angiotensina (RAS) mediante angiotensinógenos
US9403865B2 (en)	2012-08-15	2016-08-02	Ionis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified capping protocols
WO2014059353A2 (en)	2012-10-11	2014-04-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleosides and uses thereof
AR092982A1 (es)	2012-10-11	2015-05-13	Isis Pharmaceuticals Inc	Modulacion de la expresion de receptores androgenicos
US9523094B2 (en)	2012-10-11	2016-12-20	Ionis Pharmaceuticals, Inc.	Methods of treating kennedy's disease
EP2906256B1 (de)	2012-10-12	2018-08-22	Ionis Pharmaceuticals, Inc.	Selektive antisense-verbindungen und verwendungen davon
US20160138014A1 (en)	2012-10-12	2016-05-19	Isis Pharmaceuticals, Inc.	Antisense compounds and uses thereof
EP2906258A4 (de)	2012-10-15	2016-08-10	Ionis Pharmaceuticals Inc	Zusammensetzungen zur modulierung der c9orf72-expression
WO2014062736A1 (en)	2012-10-15	2014-04-24	Isis Pharmaceuticals, Inc.	Methods for monitoring c9orf72 expression
US9963699B2 (en)	2012-10-15	2018-05-08	Ionis Pharmaceuticals, Inc.	Methods for modulating C9ORF72 expression
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2014066239A1 (en)	2012-10-22	2014-05-01	Idenix Pharmaceuticals, Inc.	2',4'-bridged nucleosides for hcv infection
JP6542669B2 (ja)	2012-10-31	2019-07-10	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	癌の治療
WO2014071358A2 (en)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Novel ntrk1 fusion molecules and uses thereof
DK2920304T3 (da)	2012-11-15	2019-05-13	Roche Innovation Ct Copenhagen As	Oligonukleotidkonjugater
JP6463687B2 (ja)	2012-11-26	2019-02-06	ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅＩｎｎｏｖａｔｉｏｎＣｅｎｔｅｒＣｏｐｅｎｈａｇｅｎＡ／Ｓ	Ｆｇｆｒ３の発現の調節のための組成物及び方法
RS63237B1 (sr)	2012-11-26	2022-06-30	Modernatx Inc	Terminalno modifikovana rnk
US9695475B2 (en)	2012-12-11	2017-07-04	Ionis Pharmaceuticals, Inc.	Competitive modulation of microRNAs
JPWO2014112463A1 (ja) *	2013-01-15	2017-01-19	国立大学法人大阪大学	スルホンアミド構造を有するヌクレオシドおよびヌクレオチド
CA2897941A1 (en)	2013-01-17	2014-07-24	Moderna Therapeutics, Inc.	Signal-sensor polynucleotides for the alteration of cellular phenotypes
US10980804B2 (en)	2013-01-18	2021-04-20	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
DK2951305T3 (en)	2013-01-30	2018-10-29	Hoffmann La Roche	LNA oligonucleotide KULHYDRATKONJUGATER
WO2014118272A1 (en)	2013-01-30	2014-08-07	Santaris Pharma A/S	Antimir-122 oligonucleotide carbohydrate conjugates
EP2951191B1 (de)	2013-01-31	2018-10-17	Ionis Pharmaceuticals, Inc.	Verfahren zur herstellung oligomerer verbindungen unter verwendung von modifizierten kopplungsprotokollen
EP3778618A1 (de)	2013-02-04	2021-02-17	Ionis Pharmaceuticals, Inc.	Selektive antisense-verbindungen und verwendungen davon
US9593333B2 (en)	2013-02-14	2017-03-14	Ionis Pharmaceuticals, Inc.	Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations
US20150366890A1 (en)	2013-02-25	2015-12-24	Trustees Of Boston University	Compositions and methods for treating fungal infections
EP2968391A1 (de)	2013-03-13	2016-01-20	Moderna Therapeutics, Inc.	Langlebige polynukleotidmoleküle
WO2014143158A1 (en)	2013-03-13	2014-09-18	The Broad Institute, Inc.	Compositions and methods for labeling of agents
ES2807379T3 (es)	2013-03-14	2021-02-22	Ionis Pharmaceuticals Inc	Composiciones y métodos para regular la expresión de Tau
US9273349B2 (en)	2013-03-14	2016-03-01	Affymetrix, Inc.	Detection of nucleic acids
CN105229150A (zh)	2013-03-14	2016-01-06	安第斯生物技术股份有限公司	用于治疗癌症干细胞的反义寡核苷酸
BR112015022876B1 (pt)	2013-03-14	2022-03-15	Alnylam Pharmaceuticals, Inc	Agente de rna fita dupla, composição farmacêutica e método para inibição da expressão do componente do complemento c5 em uma célula
US10258698B2 (en)	2013-03-14	2019-04-16	Modernatx, Inc.	Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP2970364B1 (de)	2013-03-14	2019-04-24	Andes Biotechnologies Global, Inc.	Verfahren zur erkennung und behandlung von multiplem myelom
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
WO2014172698A1 (en)	2013-04-19	2014-10-23	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation nucleic acids through nonsense mediated decay
MY178929A (en)	2013-05-01	2020-10-23	Glaxo Group Ltd	Compositions and methods for modulating hbv and ttr expression
CN105164261B (zh)	2013-05-01	2022-03-18	莱古路斯治疗法股份有限公司	用于增强的细胞摄取的化合物和方法
NZ630890A (en)	2013-05-01	2017-09-29	Regulus Therapeutics Inc	Microrna compounds and methods for modulating mir-122
IL285780B (en)	2013-05-22	2022-07-01	Alnylam Pharmaceuticals Inc	Tmprss6 irna compositions and methods of use thereof
TWI664187B (zh)	2013-05-22	2019-07-01	阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
JP2016520310A (ja)	2013-05-24	2016-07-14	ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅＩｎｎｏｖａｔｉｏｎＣｅｎｔｅｒＣｏｐｅｎｈａｇｅｎＡ／Ｓ	Ｂ細胞ｃｌｌ／リンパ腫１１ａ（ｂｃｌ１１ａ）のオリゴヌクレオチドモデュレーター及びその使用
US20160113911A1 (en)	2013-06-06	2016-04-28	The General Hospital Corporation	Methods and compositions for the treatment of cancer
WO2014205449A2 (en)	2013-06-21	2014-12-24	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
CA2916252A1 (en)	2013-06-21	2014-12-24	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation of target nucleic acids
EP3591054A1 (de)	2013-06-27	2020-01-08	Roche Innovation Center Copenhagen A/S	Gegen pcsk9 gerichtete antisense-oligomere und konjugate
BR112015033069A2 (pt)	2013-07-02	2017-11-07	Ionis Pharmaceuticals Inc	moduladores de receptor do hormônio de crescimento
SI3019619T1 (sl)	2013-07-11	2021-12-31	Modernatx, Inc.	Sestave, ki zajemajo sintetične polinukleotide, ki kodirajo proteine, pozvezane s crispr, in sintetične sgrna, ter metode uporabe
JP6617702B2 (ja)	2013-07-15	2019-12-11	ザリージェンツオブザユニバーシティオブカリフォルニア	Ｆｔｙ７２０のアザサイクリック拘束アナログ
TWI657819B (zh)	2013-07-19	2019-05-01	美商Ionis製藥公司	用於調節τ蛋白表現之組合物
US10435430B2 (en)	2013-07-31	2019-10-08	Ionis Pharmaceuticals, Inc.	Methods and compounds useful in conditions related to repeat expansion
AU2014306271A1 (en)	2013-08-08	2016-03-24	The Scripps Research Institute	A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides
TW201536329A (zh)	2013-08-09	2015-10-01	Isis Pharmaceuticals Inc	用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
CA2921839A1 (en)	2013-08-28	2015-03-05	Ionis Pharmaceuticals, Inc.	Modulation of prekallikrein (pkk) expression
US20160194368A1 (en)	2013-09-03	2016-07-07	Moderna Therapeutics, Inc.	Circular polynucleotides
AU2014315287A1 (en)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Chimeric polynucleotides
MY181251A (en)	2013-09-13	2020-12-21	Ionis Pharmaceuticals Inc	Modulators of complement factor b
WO2015042447A1 (en)	2013-09-20	2015-03-26	Isis Pharmaceuticals, Inc.	Targeted therapeutic nucleosides and their use
TW202003849A (zh)	2013-10-02	2020-01-16	美商艾爾妮蘭製藥公司	抑制lect2基因表現之組合物及方法
JP2016538829A (ja)	2013-10-03	2016-12-15	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	低密度リポタンパク質受容体をコードするポリヌクレオチド
PE20211249A1 (es)	2013-10-04	2021-07-13	Alnylam Pharmaceuticals Inc	PRODUCTO DE FARMACO DE siARN PARA INHIBIR LA EXPRESION DE ALAS1 Y COMPOSICION QUE LO COMPRENDE
SG10201808903UA (en)	2013-10-11	2018-11-29	Ionis Pharmaceuticals Inc	Compositions for modulating c9orf72 expression
US11162096B2 (en)	2013-10-14	2021-11-02	Ionis Pharmaceuticals, Inc	Methods for modulating expression of C9ORF72 antisense transcript
US9758546B2 (en)	2013-10-21	2017-09-12	Ionis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
EP3967770B1 (de)	2013-10-21	2023-12-06	The General Hospital Corporation	Verfahren im zusammenhang mit zirkulierenden tumorzellclustern und mit der behandlung von krebs
US9994846B2 (en)	2013-10-25	2018-06-12	Regulus Therapeutics Inc.	MicroRNA compounds and methods for modulating miR-21 activity
DK3066219T3 (en)	2013-11-08	2019-03-11	Ionis Pharmaceuticals Inc	METHODS FOR DETECTING OIGONUCLEOTIDES
EP3750997A1 (de)	2013-12-02	2020-12-16	Ionis Pharmaceuticals, Inc.	Antisense-verbindungen und verwendungen davon
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
CA3107872A1 (en)	2013-12-12	2015-06-18	Alnylam Pharmaceuticals, Inc.	Complement component irna compositions and methods of use thereof
WO2015095527A1 (en)	2013-12-20	2015-06-25	The General Hosptial Corporation	Methods and assays relating to circulating tumor cells
CN111394355A (zh)	2013-12-24	2020-07-10	Ionis制药公司	促血管生成素样3表达的调节
EP3095460A4 (de)	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chirales nukleinsäureadjuvans mit antiallergischer wirkung und antiallergikum
JPWO2015108047A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108048A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
CN106068325B (zh)	2014-01-16	2021-07-09	波涛生命科学有限公司	手性设计
KR102389968B1 (ko)	2014-02-11	2022-04-25	알닐람 파마슈티칼스 인코포레이티드	케토헥소키나제(ＫＨＫ) ｉＲＮＡ 조성물 및 그의 사용 방법
EP3119789B1 (de)	2014-03-17	2020-04-22	Ionis Pharmaceuticals, Inc.	Bicyclische carbocyclische nukleoside und daraus hergestellte oligomere verbindungen
US10308934B2 (en)	2014-03-19	2019-06-04	Ionis Pharmaceuticals, Inc.	Compositions for modulating Ataxin 2 expression
US10006027B2 (en)	2014-03-19	2018-06-26	Ionis Pharmaceuticals, Inc.	Methods for modulating Ataxin 2 expression
CN111440798A (zh)	2014-04-01	2020-07-24	比奥根Ma公司	用于调节sod-1表达的组合物
US10513706B2 (en)	2014-04-09	2019-12-24	The Scripps Research Institute	Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
ES2932304T3 (es)	2014-04-17	2023-01-17	Biogen Ma Inc	Composiciones y métodos para la modulación del empalme de SMN2 en un sujeto
US10221416B2 (en)	2014-04-24	2019-03-05	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising alpha-beta-constrained nucleic acid
WO2015168172A1 (en)	2014-04-28	2015-11-05	Isis Pharmaceuticals, Inc.	Linkage modified oligomeric compounds
EP3862362A3 (de)	2014-05-01	2021-10-27	Ionis Pharmaceuticals, Inc.	Konjugate con antisens-oligonukleotides und deren verwendung zur modulation der pkk-expression
EP3811977A1 (de)	2014-05-01	2021-04-28	Ionis Pharmaceuticals, Inc.	Verfahren zur synthese von reaktiven konjugatclustern
CN106459969B (zh)	2014-05-01	2019-11-15	Ionis制药公司	用于调节生长激素受体表达的组合物和方法
AU2015252895B2 (en)	2014-05-01	2021-07-15	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating angiopoietin-like 3 expression
WO2015168635A2 (en)	2014-05-01	2015-11-05	Isis Pharmaceuticals, Inc.	Compositions and methods for modulating complement factor b expression
WO2015175510A1 (en)	2014-05-12	2015-11-19	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating a serpinc1-associated disorder
GB201408623D0 (en)	2014-05-15	2014-07-02	Santaris Pharma As	Oligomers and oligomer conjugates
BR122020023687B1 (pt)	2014-05-22	2023-03-07	Alnylam Pharmaceuticals, Inc	Agente de ácido ribonucleico (rnai) de fita dupla, seus usos e composição farmacêutica
US10570169B2 (en)	2014-05-22	2020-02-25	Ionis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
EP3148564B1 (de)	2014-06-02	2020-01-08	Children's Medical Center Corporation	Verfahren und zusammensetzungen zur immunmodulation
USD766120S1 (en)	2014-06-09	2016-09-13	Gambro Lundia Ab	Status light bar
GB201410693D0 (en)	2014-06-16	2014-07-30	Univ Southampton	Splicing modulation
EP4159741A1 (de)	2014-07-16	2023-04-05	ModernaTX, Inc.	Verfahren zur herstellung eines chimären polynukleotids zur kodierung eines polypeptids mit einer triazolhaltigen internukleotid-bindung
WO2016014846A1 (en)	2014-07-23	2016-01-28	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of intrabodies
CA2953883A1 (en)	2014-08-07	2016-02-11	Regulus Therapeutics Inc.	Targeting micrornas for metabolic disorders
WO2016024205A1 (en)	2014-08-15	2016-02-18	Pfizer Inc.	Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
US10385343B2 (en)	2014-08-29	2019-08-20	Children's Medical Center Corporation	Methods and compositions for the treatment of cancer
WO2016040589A1 (en)	2014-09-12	2016-03-17	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting complement component c5 and methods of use thereof
US10436802B2 (en)	2014-09-12	2019-10-08	Biogen Ma Inc.	Methods for treating spinal muscular atrophy
EP3201339A4 (de)	2014-10-03	2018-09-19	Cold Spring Harbor Laboratory	Gezielten erhöhung der nukleären genleistung
JOP20200115A1 (ar)	2014-10-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
SG11201702877TA (en)	2014-10-10	2017-05-30	Hoffmann La Roche	Galnac phosphoramidites, nucleic acid conjugates thereof and their use
EP3207138B1 (de)	2014-10-17	2020-07-15	Alnylam Pharmaceuticals, Inc.	Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
EP3904519A1 (de)	2014-10-30	2021-11-03	Genzyme Corporation	Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
US9816080B2 (en)	2014-10-31	2017-11-14	President And Fellows Of Harvard College	Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
JOP20200092A1 (ar)	2014-11-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
US10287584B2 (en)	2014-11-12	2019-05-14	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of COMP
US10364433B2 (en)	2014-11-14	2019-07-30	The Regents Of The University Of California	Modulation of AGPAT5 expression
EP3020813A1 (de)	2014-11-16	2016-05-18	Neurovision Pharma GmbH	Antisense-Oligonukleotide als Inhibitoren der TGF-R-Signalgebung
CN113846101A (zh)	2014-11-17	2021-12-28	阿尔尼拉姆医药品有限公司	载脂蛋白C3（APOC3）iRNA组合物及其使用方法
US10400243B2 (en)	2014-11-25	2019-09-03	Ionis Pharmaceuticals, Inc.	Modulation of UBE3A-ATS expression
EP4088741A1 (de)	2014-12-08	2022-11-16	The Board of Regents of the University of Texas System	Lipokationische polymere und verwendungen davon
DK3234131T3 (da)	2014-12-16	2020-06-29	Roche Innovation Ct Copenhagen As	Fremgangsmåde til screening af kiral toksicitet
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016112132A1 (en)	2015-01-06	2016-07-14	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
WO2016115490A1 (en)	2015-01-16	2016-07-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulation of dux4
CR20170359A (es)	2015-02-04	2017-11-24	Hoffmann La Roche	Oligómetros antisentido de tau y usos de estos
CN115181778A (zh)	2015-02-04	2022-10-14	百时美施贵宝公司	选择治疗性分子的方法
US10758558B2 (en)	2015-02-13	2020-09-01	Translate Bio Ma, Inc.	Hybrid oligonucleotides and uses thereof
AU2016219263B2 (en)	2015-02-13	2022-12-01	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
US10426789B2 (en)	2015-02-26	2019-10-01	Ionis Pharmaceuticals, Inc.	Allele specific modulators of P23H rhodopsin
EP3265098B1 (de)	2015-03-03	2025-03-26	Ionis Pharmaceuticals, Inc.	Zusammensetzungen zur modulierung der mecp2 -expression
ES2909308T3 (es)	2015-03-03	2022-05-06	Ionis Pharmaceuticals Inc	Métodos para modular la expresión de MECP2
US11129844B2 (en)	2015-03-03	2021-09-28	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating MECP2 expression
CA2981068C (en)	2015-03-26	2021-12-14	Women & Infants Hospital Of Rhode Island	Therapy for malignant disease comprising the inhibition of human epididymal secretory protein e4 and immune checkpoint inhibitors
KR102539587B1 (ko)	2015-04-03	2023-06-01	아이오니스 파마수티컬즈, 인코포레이티드	Tmprss6 발현을 조절하기 위한 화합물 및 방법들
US10745702B2 (en)	2015-04-08	2020-08-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the LECT2 gene
SG10202001856WA (en)	2015-04-16	2020-04-29	Ionis Pharmaceuticals Inc	Compositions for modulating c9orf72 expression
WO2016167780A1 (en)	2015-04-16	2016-10-20	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
WO2016201301A1 (en)	2015-06-12	2016-12-15	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions and methods of use thereof
EP3310918B1 (de)	2015-06-18	2020-08-05	Alnylam Pharmaceuticals, Inc.	Gegen hydroxysäureoxidase (glycolat-oxidase, hao1) gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
WO2016205681A1 (en)	2015-06-19	2016-12-22	University Of Rochester	Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
JP2018519811A (ja)	2015-06-29	2018-07-26	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	修飾ｃｒｉｓｐｒｒｎａ及び修飾単一ｃｒｉｓｐｒｒｎａならびにその使用
WO2017011286A1 (en)	2015-07-10	2017-01-19	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
US20180312845A1 (en)	2015-07-10	2018-11-01	Ionis Pharmaceuticals, Inc.	Modulators of diacyglycerol acyltransferase 2 (dgat2)
MA43072A (fr)	2015-07-22	2018-05-30	Wave Life Sciences Ltd	Compositions d'oligonucléotides et procédés associés
WO2017024111A1 (en)	2015-08-04	2017-02-09	The University Of Chicago	Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
CN107922945A (zh)	2015-08-24	2018-04-17	罗氏创新中心哥本哈根有限公司	Lna‑g 方法
EA201890619A1 (ru)	2015-09-02	2018-09-28	Элнилэм Фармасьютикалз, Инк.	КОМПОЗИЦИИ iRNA ЛИГАНДА 1 БЕЛКА ЗАПРОГРАММИРОВАННОЙ ГИБЕЛИ КЛЕТОК 1 (PD-L1) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2017048789A1 (en)	2015-09-14	2017-03-23	The Board Of Regents Of The University Of Texas System	Lipocationic dendrimers and uses thereof
SG10201913209WA (en)	2015-09-24	2020-02-27	Ionis Pharmaceuticals Inc	Modulators of kras expression
JP6853539B2 (ja)	2015-09-24	2021-03-31	ザリージェンツオブザユニバーシティオブカリフォルニアＴｈｅＲｅｇｅｎｔｓＯｆＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＣａｌｉｆｏｒｎｉａ	合成スフィンゴ脂質様分子、薬物、これらの合成方法、および処置方法
PT3353303T (pt)	2015-09-25	2023-10-10	Academisch Ziekenhuis Leiden	Composições e métodos para modulação da expressão de ataxina 3
MX2018004307A (es)	2015-10-08	2018-05-01	Ionis Pharmaceuticals Inc	Composiciones y metodos para modular la expresion de angiotensinogeno.
US10196639B2 (en)	2015-10-09	2019-02-05	University Of Southampton	Modulation of gene expression and screening for deregulated protein expression
EP3362462B1 (de)	2015-10-12	2021-07-21	Advanced Cell Diagnostics, Inc.	In-situ-detektion von nukleotidvarianten bei proben mit hohem rauschen sowie zugehörige zusammensetzungen und verfahren
WO2017068087A1 (en)	2015-10-22	2017-04-27	Roche Innovation Center Copenhagen A/S	Oligonucleotide detection method
EP3394258B1 (de)	2015-10-22	2021-09-22	Roche Innovation Center Copenhagen A/S	Test für in-vitro-toxizitätsscreening
US11260073B2 (en)	2015-11-02	2022-03-01	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating C90RF72
EP4119569B1 (de)	2015-11-06	2024-07-31	Ionis Pharmaceuticals, Inc.	Konjugierte antisense-verbindungen zur verwendung in der therapie
EP3370708A4 (de)	2015-11-06	2019-06-26	Ionis Pharmaceuticals, Inc.	Modulation der apolipoprotein (a)-expression
SI3374509T1 (sl)	2015-11-12	2021-04-30	F. Hoffmann-La Roche Ag	Oligonukleotidi za indukcijo očetovske ekspresije UBE3A
US11058709B1 (en)	2015-12-04	2021-07-13	Ionis Pharmaceuticals, Inc.	Methods of treating breast cancer
RU2021124592A (ru)	2015-12-07	2021-11-01	Джензим Корпорейшн	Способы и композиции для лечения ассоциированного с serpinc1 расстройства
US11096956B2 (en)	2015-12-14	2021-08-24	Stoke Therapeutics, Inc.	Antisense oligomers and uses thereof
KR102604132B1 (ko)	2015-12-14	2023-11-17	콜드스프링하버러보러토리	상염색체 우성 정신 지체 5 및 드라베 증후군의 치료를 위한 안티센스 올리고머
WO2017106767A1 (en)	2015-12-18	2017-06-22	The Scripps Research Institute	Production of unnatural nucleotides using a crispr/cas9 system
WO2017111137A1 (ja) *	2015-12-22	2017-06-29	味の素株式会社	オリゴヌクレオチドの製造方法
WO2017117496A1 (en)	2015-12-31	2017-07-06	Ionis Pharmaceuticals, Inc.	Methods for reducing ataxin-2 expression
AU2017205462A1 (en)	2016-01-05	2018-06-07	Ionis Pharmaceuticals, Inc.	Methods for reducing LRRK2 expression
EP4354140A3 (de)	2016-02-26	2024-07-24	The Board of Trustees of the Leland Stanford Junior University	Multiplexierte einzelmolekül-rna-visualisierung mit einem zwei-sonden-proximitätsligationssystem
EP3423581A4 (de)	2016-03-04	2020-03-04	Rhode Island Hospital	Targeting von mikrorna zur krebsbehandlung
WO2017156242A1 (en)	2016-03-09	2017-09-14	Ionis Pharmaceuticals, Inc.	Methods and compositions for inhibiting pmp22 expression
EP3430141B1 (de)	2016-03-14	2020-12-30	H. Hoffnabb-La Roche Ag	Oligonukleotide zur reduktion der pd-l1-expression
US10577607B2 (en)	2016-03-16	2020-03-03	Ionis Pharmaceuticals, Inc.	Modulation of DYRK1B expression
CA3013799A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Methods of modulating keap1
CN108779139A (zh)	2016-03-18	2018-11-09	罗氏创新中心哥本哈根有限公司	酰基保护的l-lna-鸟嘌呤核苷单体
CA3017532A1 (en)	2016-04-13	2017-10-19	Ionis Pharmaceuticals, Inc.	Methods for reducing c9orf72 expression
JP6985288B2 (ja)	2016-04-14	2021-12-22	エフ.ホフマン−ラロシュアーゲーF. Hoffmann−La Roche Aktiengesellschaft	トリチル−モノ−ＧａｌＮＡｃ化合物とその利用
MA45295A (fr)	2016-04-19	2019-02-27	Alnylam Pharmaceuticals Inc	Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
KR102706686B1 (ko)	2016-05-06	2024-09-19	아이오니스 파마수티컬즈, 인코포레이티드	Glp-1 수용체 리간드 모이어티 컨쥬게이트된 올리고뉴클레오티드 및 이의 용도
CN109311925B (zh) *	2016-05-12	2022-06-03	罗氏创新中心哥本哈根有限公司	立体限定的氧杂氮杂磷杂环戊烷亚磷酰胺单体与核苷或寡核苷酸的增强的偶联
AU2017267634C1 (en)	2016-05-16	2022-05-26	The Board Of Regents Of The University Of Texas System	Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
JP6876383B2 (ja) *	2016-06-07	2021-05-26	富士通オプティカルコンポーネンツ株式会社	波長可変光源
US20190256845A1 (en)	2016-06-10	2019-08-22	Alnylam Pharmaceuticals, Inc.	COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
EP3468981B1 (de)	2016-06-14	2024-07-24	Biogen MA Inc.	Verfahren zur reinigung von oligonukleotiden unter verwendung von hydrophober chromatographie
CA3023514A1 (en)	2016-06-17	2017-12-21	Ionis Pharmaceuticals, Inc.	Modulation of gys1 expression
EP3472347B1 (de)	2016-06-17	2023-01-04	F. Hoffmann-La Roche AG	In-vitro-screeningtests für nephrotoxizität
MA45496A (fr)	2016-06-17	2019-04-24	Hoffmann La Roche	Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
EP3472348B1 (de)	2016-06-17	2022-06-29	F. Hoffmann-La Roche AG	In-vitro-screeningtests für nephrotoxizität
DK3475295T3 (da)	2016-06-24	2022-10-24	Scripps Research Inst	Hidtil ukendt nukleosidtriphosphat-transportør og anvendelser deraf
SG11201811554SA (en)	2016-07-01	2019-01-30	Hoffmann La Roche	Antisense oligonucleotides for modulating htra1 expression
EP3507367A4 (de)	2016-07-05	2020-03-25	Aduro BioTech, Inc.	Cyclisches dinukleotidverbindungen mit eingeschlossenen nukleinsäuren und verwendungen davon
AU2017296195A1 (en)	2016-07-11	2019-01-24	Translate Bio Ma, Inc.	Nucleic acid conjugates and uses thereof
PT3484524T (pt)	2016-07-15	2023-02-15	Ionis Pharmaceuticals Inc	Composições e métodos para a modulação de smn2
JOP20190065A1 (ar)	2016-09-29	2019-03-28	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن tau
EP3518981A4 (de)	2016-10-03	2020-06-10	President and Fellows of Harvard College	Abgabe von therapeutischen rnas über arrdc1-vermittelte mikrovesikel
KR20190065341A (ko)	2016-10-06	2019-06-11	아이오니스 파마수티컬즈, 인코포레이티드	올리고머 화합물들의 접합 방법
JOP20190104A1 (ar)	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
US20190284621A1 (en)	2016-11-11	2019-09-19	Roche Innovation Center Copenhagen A/S	Therapeutic oligonucleotides capture and detection
TWI788312B (zh)	2016-11-23	2023-01-01	美商阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
EP4035659A1 (de)	2016-11-29	2022-08-03	PureTech LYT, Inc.	Exosome zur ausgabe von therapeutischen wirkstoffen
US11033570B2 (en)	2016-12-02	2021-06-15	Cold Spring Harbor Laboratory	Modulation of Lnc05 expression
EP3555292A1 (de)	2016-12-16	2019-10-23	Alnylam Pharmaceuticals, Inc.	Verfahren zur behandlung oder prävention von ttr-assoziierten krankheiten unter verwendung von transthyretin (ttr)-irna-zusammensetzungen
WO2018130584A1 (en)	2017-01-13	2018-07-19	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating nfkb2 expression
US20190338286A1 (en)	2017-01-13	2019-11-07	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating rel expression
WO2018130581A1 (en)	2017-01-13	2018-07-19	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating rela expression
EP3568479A1 (de)	2017-01-13	2019-11-20	Roche Innovation Center Copenhagen A/S	Antisense-oligonukleotide zur modulierung der nfkb1-expression
US20190345496A1 (en)	2017-01-13	2019-11-14	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating relb expression
WO2018165564A1 (en)	2017-03-09	2018-09-13	Ionis Pharmaceuticals, Inc.	Morpholino modified oligomeric compounds
JOP20190215A1 (ar)	2017-03-24	2019-09-19	Ionis Pharmaceuticals Inc	مُعدّلات التعبير الوراثي عن pcsk9
WO2018177825A1 (en)	2017-03-29	2018-10-04	Roche Innovation Center Copenhagen A/S	Orthogonal protecting groups for the preparation of stereodefined phosphorothioate oligonucleotides
WO2018195165A1 (en)	2017-04-18	2018-10-25	Alnylam Pharmaceuticals, Inc.	Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
US20190055564A1 (en)	2017-06-01	2019-02-21	F. Hoffmann-La Roche Ag	Antisense oligonucleotides for modulating htra1 expression
EP3599844A4 (de)	2017-06-07	2021-01-13	University of Massachusetts	Anti-adam33-oligonukleotide und zugehörige verfahren
US11814407B2 (en)	2017-06-28	2023-11-14	Roche Innovation Center Copenhagen A/S	Multiple coupling and oxidation method
WO2019014267A1 (en)	2017-07-11	2019-01-17	Synthorx, Inc.	INCORPORATION OF NON-NATURAL NUCLEOTIDES AND ASSOCIATED METHODS
CA3069868A1 (en)	2017-07-13	2019-01-17	Alnylam Pharmaceuticals Inc.	Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
MA49767A (fr)	2017-08-03	2021-05-26	Synthorx Inc	Conjugués de cytokine pour le traitement de maladies auto-immunes
WO2019030313A2 (en)	2017-08-11	2019-02-14	Roche Innovation Center Copenhagen A/S	OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
WO2019036613A1 (en)	2017-08-18	2019-02-21	Ionis Pharmaceuticals, Inc.	MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS
WO2019038228A1 (en)	2017-08-22	2019-02-28	Roche Innovation Center Copenhagen A/S	OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
KR102643936B1 (ko)	2017-08-25	2024-03-05	스톡 테라퓨틱스, 인크.	병태 및 질환 치료용 안티센스 올리고머
US10517889B2 (en)	2017-09-08	2019-12-31	Ionis Pharmaceuticals, Inc.	Modulators of SMAD7 expression
EP3694995A1 (de)	2017-10-13	2020-08-19	Roche Innovation Center Copenhagen A/S	Verfahren zur identifizierung verbesserter stereodefinierter phosphorothioat-oligonukleotid-varianten von antisense-oligonukleotiden unter verwendung von unterbibliotheken von teilweise stereodefinierten oligonukleotiden
KR102769100B1 (ko)	2017-10-16	2025-02-19	에프. 호프만-라 로슈 아게	B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자
CA3078971A1 (en)	2017-11-01	2019-05-09	Alnylam Pharmaceuticals, Inc.	Complement component c3 irna compositions and methods of use thereof
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
US20200385719A1 (en)	2017-11-16	2020-12-10	Alnylam Pharmaceuticals, Inc.	Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
EP3714054A1 (de)	2017-11-20	2020-09-30	Alnylam Pharmaceuticals, Inc.	Serum-amyloid p-komponente (apcs) irna zusammensetzungen und verfahren zu deren verwendung
EP3724333A2 (de)	2017-12-11	2020-10-21	Roche Innovation Center Copenhagen A/S	Oligonukleotide zur modulierung der fndc3b-expression
WO2019115417A2 (en)	2017-12-12	2019-06-20	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating rb1 expression
US11725208B2 (en)	2017-12-14	2023-08-15	Ionis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
CA3086343A1 (en)	2017-12-18	2019-06-27	Alnylam Pharmaceuticals, Inc.	High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
WO2019126641A2 (en)	2017-12-21	2019-06-27	Ionis Pharmaceuticals, Inc.	Modulation of frataxin expression
JP2021507253A (ja)	2017-12-21	2021-02-22	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｈｔｒａ１ｒｎａアンタゴニストについてのコンパニオン診断
EP4074724A1 (de)	2017-12-22	2022-10-19	Roche Innovation Center Copenhagen A/S	Oligonukleotide, die eine phosphordithioat-internukleosidverknüpfung umfassen
EP3728591A1 (de)	2017-12-22	2020-10-28	Roche Innovation Center Copenhagen A/S	Gapmer-oligonukleotide mit einer phosphordithioat-internukleosidverknüpfung
JP2021508327A (ja)	2017-12-22	2021-03-04	ロシュイノベーションセンターコペンハーゲンエーエス	新規のチオホスホラミダイト
KR102776907B1 (ko)	2017-12-29	2025-03-11	더 스크립스 리서치 인스티튜트	비천연 염기쌍 조성물 및 사용 방법
CN111699258A (zh)	2018-01-10	2020-09-22	哥本哈根罗氏创新中心	用于调控pias4表达的寡核苷酸
WO2019140102A1 (en)	2018-01-10	2019-07-18	Translate Bio Ma, Inc.	Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
CA3085964A1 (en)	2018-01-12	2019-07-18	Roche Innovation Center Copenhagen A/S	Alpha-synuclein antisense oligonucleotides and uses thereof
JP7547201B2 (ja)	2018-01-12	2024-09-09	ブリストル－マイヤーズスクイブカンパニー	アルファ－シヌクレインを標的とするアンチセンスオリゴヌクレオチドおよびその使用
WO2019140231A1 (en)	2018-01-12	2019-07-18	Bristol-Myers Squibb Company	Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2019137974A1 (en)	2018-01-12	2019-07-18	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating gsk3b expression
RU2020127049A (ru)	2018-01-15	2022-02-17	Айонис Фармасьютикалс, Инк.	Модуляторы экспрессии dnm2
US20210095276A1 (en)	2018-01-17	2021-04-01	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating erc1 expression
US20210095277A1 (en)	2018-01-18	2021-04-01	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting srebp1
WO2019145386A1 (en)	2018-01-26	2019-08-01	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating csnk1d expression
CA3088071A1 (en)	2018-02-09	2019-08-15	Genentech, Inc.	Oligonucleotides for modulating tmem106b expression
EP3752612A4 (de)	2018-02-12	2021-11-10	Ionis Pharmaceuticals, Inc.	Modifizierte verbindungen und verwendungen davon
KR20200140805A (ko)	2018-02-21	2020-12-16	브리스톨-마이어스 스큅 컴퍼니	Camk2d 안티센스 올리고뉴클레오티드 및 그의 용도
KR20200127207A (ko)	2018-02-26	2020-11-10	신톡스, 인크.	Il-15 접합체 및 이의 용도
WO2019169243A1 (en)	2018-03-02	2019-09-06	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of amyloid-beta precursor protein
TWI840345B (zh)	2018-03-02	2024-05-01	美商Ionis製藥公司	Irf4表現之調節劑
US20210054377A1 (en)	2018-03-20	2021-02-25	Tokyo Institute Of Technology	Antisense oligonucleotide reduced in toxicity
WO2019183440A1 (en)	2018-03-22	2019-09-26	Ionis Pharmaceuticals, Inc.	Methods for modulating fmr1 expression
RU2020135289A (ru)	2018-04-05	2022-05-05	Ф. Хоффманн-Ля Рош Аг	Применение ингибиторов fubp1 для лечения инфекции вирусом гепатита в
WO2019199643A1 (en)	2018-04-09	2019-10-17	Bio-Techne Corporation	Methods to further enhance signal amplification for the in situ detection of nucleic acids
WO2019200172A1 (en)	2018-04-11	2019-10-17	Ionis Pharmaceuticals, Inc.	Modulators of ezh2 expression
EP3788065A4 (de)	2018-04-30	2022-01-19	The Children's Hospital Of Philadelphia	Verfahren zur verbesserung von anämien durch kombination von wirkstoffen
EP3788169A4 (de)	2018-05-04	2022-08-10	Stoke Therapeutics, Inc.	Verfahren und zusammensetzungen zur behandlung von cholesterinesterspeicherkrankheit
US20210071247A1 (en)	2018-05-07	2021-03-11	Roche Innovation Center Copenhagen A/S	Massively parallel discovery methods for oligonucleotide therapeutics
US20210371860A1 (en)	2018-05-08	2021-12-02	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating myh7 expression
KR20210008497A (ko)	2018-05-09	2021-01-22	아이오니스 파마수티컬즈, 인코포레이티드	Atxn3 발현 감소용 화합물 및 방법
KR20210008498A (ko)	2018-05-09	2021-01-22	아이오니스 파마수티컬즈, 인코포레이티드	Fxi 발현을 감소시키기 위한 화합물 및 방법
TWI851574B (zh)	2018-05-14	2024-08-11	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
EP3793685A1 (de)	2018-05-18	2021-03-24	F. Hoffmann-La Roche AG	Pharmazeutische zusammensetzungen zur behandlung von krankheiten im zusammenhang mit mikro-rna
WO2019224172A1 (en)	2018-05-25	2019-11-28	Roche Innovation Center Copenhagen A/S	Novel process for making allofuranose from glucofuranose
US11066669B2 (en)	2018-06-05	2021-07-20	Hoffmann-La Roche Inc.	Oligonucleotides for modulating ATXN2 expression
US11833168B2 (en)	2018-06-14	2023-12-05	Ionis Pharmaceuticals, Inc.	Compounds and methods for increasing STMN2 expression
TWI833770B (zh)	2018-06-27	2024-03-01	美商Ionis製藥公司	用於減少 lrrk2 表現之化合物及方法
WO2020007772A1 (en)	2018-07-02	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting gbp-1
WO2020007702A1 (en)	2018-07-02	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting bcl2l11
WO2020007700A1 (en)	2018-07-02	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting spi1
MX2020013366A (es)	2018-07-03	2021-03-09	Hoffmann La Roche	Oligonucleotidos para modular la expresion de tau.
WO2020007889A1 (en)	2018-07-05	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting stat1
WO2020007826A1 (en)	2018-07-05	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting mbtps1
WO2020011743A1 (en)	2018-07-09	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting mafb
WO2020011653A1 (en)	2018-07-09	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting kynu
WO2020011745A2 (en)	2018-07-11	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting cers6
WO2020011869A2 (en)	2018-07-11	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting tlr2
WO2020011744A2 (en)	2018-07-11	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting cers5
WO2020011902A1 (en)	2018-07-13	2020-01-16	F. Hoffmann-La Roche Ag	Oligonucleotides for modulating rtel1 expression
AU2019310097A1 (en)	2018-07-25	2021-02-04	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing ATXN2 expression
CN112236439A (zh)	2018-07-31	2021-01-15	罗氏创新中心哥本哈根有限公司	包含三硫代磷酸酯核苷间键的寡核苷酸
PL3830102T3 (pl)	2018-07-31	2022-10-03	Roche Innovation Center Copenhagen A/S	Oligonukleotydy zawierające tritiofosforanowe wiązanie międzynukleozydowe
EA202190528A1 (ru)	2018-08-13	2021-04-23	Элнилэм Фармасьютикалз, Инк.	КОМПОЗИЦИИ АГЕНТОВ дцРНК ВИРУСА ГЕПАТИТА B (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP3837381A1 (de)	2018-08-15	2021-06-23	Illumina, Inc.	Zusammensetzungen und verfahren zur verbesserung der bibliotheksanreicherung
WO2020037125A1 (en)	2018-08-16	2020-02-20	Alnylam Pharmaceuticals Inc.	Compositions and methods for inhibiting expression of the lect2 gene
EP3840733A4 (de)	2018-08-20	2022-07-20	Rogcon, Inc.	Gegen scn2a gerichtete antisense-oligonukleotide zur behandlung von scn1a-enzephalopathien
WO2020038973A1 (en)	2018-08-23	2020-02-27	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting sptlc1
WO2020038976A1 (en)	2018-08-23	2020-02-27	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting usp8
EP3841220A1 (de)	2018-08-23	2021-06-30	Roche Innovation Center Copenhagen A/S	Mikrorna-134-biomarker
WO2020038971A1 (en)	2018-08-23	2020-02-27	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting vcan
CN113728102A (zh)	2018-08-28	2021-11-30	罗氏创新中心哥本哈根有限公司	使用剪接调节化合物进行新抗原工程化
EP3620519A1 (de)	2018-09-04	2020-03-11	F. Hoffmann-La Roche AG	Verwendung von isolierten extrazellulären vesikeln aus milch zur oralen verabreichung von oligonukleotiden
EP3620520A1 (de)	2018-09-10	2020-03-11	Universidad del Pais Vasco	Neuartiges target zur behandlung einer stoffwechselerkrankung in einem individuum
WO2020060986A1 (en)	2018-09-18	2020-03-26	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
TWI856973B (zh)	2018-09-19	2024-10-01	美商Ionis製藥公司	Pnpla3表現之調節劑
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
EP3873920A1 (de)	2018-11-01	2021-09-08	F. Hoffmann-La Roche AG	Gegen tia1 gerichtete antisense-oligonukleotide
KR20210090217A (ko) *	2018-11-08	2021-07-19	알리고스 테라퓨틱스 인코포레이티드	S-항원 수송 저해 올리고뉴클레오타이드 중합체 및 방법
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
EA202191342A1 (ru)	2018-11-15	2021-08-10	Айонис Фармасьютикалз, Инк.	Модуляторы экспрессии irf5
KR20210093970A (ko)	2018-11-21	2021-07-28	아이오니스 파마수티컬즈, 인코포레이티드	프리온 발현을 감소시키기 위한 화합물 및 방법
EP3883941A1 (de)	2018-11-22	2021-09-29	Roche Innovation Center Copenhagen A/S	Pyridiniumsalze als aktivatoren bei der synthese von stereodefinierten oligonukleotiden
WO2020109343A1 (en)	2018-11-29	2020-06-04	F. Hoffmann-La Roche Ag	Combination therapy for treatment of macular degeneration
WO2020109344A1 (en)	2018-11-29	2020-06-04	F. Hoffmann-La Roche Ag	Occular administration device for antisense oligonucleotides
EP3897672B1 (de)	2018-12-20	2023-08-09	VIR Biotechnology, Inc.	Kombinierte hbv-therapie
US20220056455A1 (en)	2018-12-20	2022-02-24	Praxis Precision Medicines, Inc.	Compositions and methods for the treatment of kcnt1 related disorders
US20220042011A1 (en)	2018-12-21	2022-02-10	Hoffmann-La Roche Inc.	Antisense oligonucleotides targeting card9
AU2020209186A1 (en)	2019-01-16	2021-09-09	Genzyme Corporation	Serpinc1 iRNA compositions and methods of use thereof
CN113365607A (zh)	2019-01-25	2021-09-07	豪夫迈·罗氏有限公司	用于口服药物递送的脂质囊泡
BR112021013369A2 (pt)	2019-01-31	2021-09-21	Ionis Pharmaceuticals, Inc.	Moduladores de expressão de yap1
MX2021009259A (es)	2019-02-06	2021-08-24	Synthorx Inc	Conjugados de il-2 y metodos de uso del mismo.
JP7531502B2 (ja)	2019-02-15	2024-08-09	アドヴァンスドセルダイアグノスティクス，インコーポレイテッド	ｉｎｓｉｔｕハイブリダイゼーションによって、核酸をマルチプレックス検出する方法
AU2020225336A1 (en)	2019-02-20	2021-08-19	Roche Innovation Center Copenhagen A/S	Novel phosphoramidites
MX2021009950A (es)	2019-02-20	2021-09-21	Roche Innovation Ct Copenhagen As	Oligonucleotidos gapmeros de fosfonoacetato.
JP7503072B2 (ja)	2019-02-26	2024-06-19	ロシュイノベーションセンターコペンハーゲンエーエス	オリゴヌクレオチドの製剤化方法
CA3131700A1 (en)	2019-02-27	2020-09-03	Ionis Pharmaceuticals, Inc.	Modulators of malat1 expression
US12215382B2 (en)	2019-03-01	2025-02-04	The General Hospital Corporation	Liver protective MARC variants and uses thereof
CN113507942A (zh)	2019-03-05	2021-10-15	豪夫迈·罗氏有限公司	分子的细胞内靶向
US20240108747A1 (en)	2019-03-21	2024-04-04	Lonza Sales Ag	Extracellular vesicle conjugates and uses thereof
WO2020191177A1 (en)	2019-03-21	2020-09-24	Sudhir Agrawal	Antisense oligonucleotides for allele specificity
SG11202110674XA (en)	2019-03-29	2021-10-28	Mitsubishi Tanabe Pharma Corp	Compound, method and pharmaceutical composition for modulating expression of dux4
PE20220284A1 (es)	2019-03-29	2022-02-25	Ionis Pharmaceuticals Inc	Compuestos y metodos para modular ube3a-ats
WO2020206115A2 (en)	2019-04-03	2020-10-08	Bristol-Myers Squibb Company	Angptl2 antisense oligonucleotides and uses thereof
US11286485B2 (en)	2019-04-04	2022-03-29	Hoffmann-La Roche Inc.	Oligonucleotides for modulating ATXN2 expression
WO2020201339A1 (en)	2019-04-04	2020-10-08	F. Hoffmann-La Roche Ag	Oligonucleotides for modulating atxn2 expression
CN113661168A (zh)	2019-04-16	2021-11-16	罗氏创新中心哥本哈根有限公司	用于制备核苷酸p(v)单体的新方法
CN113767108A (zh)	2019-04-30	2021-12-07	罗氏创新中心哥本哈根有限公司	制备铼螯合mag3寡核苷酸的新方法
EP3963072A1 (de)	2019-05-03	2022-03-09	Dicerna Pharmaceuticals, Inc.	Doppelsträngige nukleinsäure-inhibitor-moleküle mit verkürzten sense-strängen
EP3966328A4 (de)	2019-05-06	2023-10-18	University Of Massachusetts	Anti-c9orf72-oligonukleotide und zugehörige verfahren
MX2021013698A (es)	2019-05-13	2021-12-10	Vir Biotechnology Inc	Composiciones y metodos para el tratamiento de la infeccion por virus de la hepatitis b (vhb).
EP3976791A4 (de)	2019-05-28	2023-10-11	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur verringerung der fus-expression
EP3980539A1 (de)	2019-06-06	2022-04-13	F. Hoffmann-La Roche AG	Gegen atxn3 gerichtete antisense-oligonukleotide
EP3983543A4 (de)	2019-06-14	2023-05-03	The Scripps Research Institute	Reagenzien und verfahren zur replikation, transkription und translation in halbsynthetischen organismen
US11786546B2 (en)	2019-07-26	2023-10-17	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating GFAP
EP4007811A2 (de)	2019-08-01	2022-06-08	Alnylam Pharmaceuticals, Inc.	Carboxypeptidase-b2(cpb2)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2021022109A1 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4013870A1 (de)	2019-08-13	2022-06-22	Alnylam Pharmaceuticals, Inc.	Irna-wirkstoffzusammensetzungen der kleinen ribosomalen proteinuntereinheit 25 (rps25) und verfahren zu ihrer verwendung
JP2022544289A (ja)	2019-08-14	2022-10-17	コディアックバイオサイエンシーズ，インコーポレイテッド	Ｓｔａｔ６を標的とする細胞外小胞－ａｓｏ構築物
US20230132093A1 (en)	2019-08-14	2023-04-27	Codiak Biosciences, Inc.	Extracellular vesicle-nlrp3 antagonist
CN114641570A (zh)	2019-08-14	2022-06-17	科迪亚克生物科学公司	具有靶向kras的反义寡核苷酸的细胞外囊泡
MX2022001769A (es)	2019-08-14	2022-06-09	Codiak Biosciences Inc	Construcciones de vesícula extracelular-oligonucleótido antisentido (aso) que se dirigen a la proteína beta de unión al potenciador ccaat (cebp)/beta.
BR112022002599A2 (pt)	2019-08-14	2022-07-19	Codiak Biosciences Inc	Vesícula extracelular ligada a moléculas e usos da mesma
WO2021030768A1 (en)	2019-08-14	2021-02-18	Codiak Biosciences, Inc.	Extracellular vesicles with stat3-antisense oligonucleotides
CN114555621A (zh)	2019-08-15	2022-05-27	Ionis制药公司	键修饰的寡聚化合物及其用途
JP2022544280A (ja)	2019-08-15	2022-10-17	シンソークス，インコーポレイテッド	Ｉｌ－２コンジュゲートを用いる免疫腫瘍学併用療
EP4017540A1 (de)	2019-08-23	2022-06-29	Synthorx, Inc.	Il-15-konjugate und verwendungen davon
JP2022546570A (ja)	2019-09-03	2022-11-04	アルナイラムファーマシューティカルズ，インコーポレイテッド	Ｌｅｃｔ２遺伝子の発現を阻害するための組成物および方法
AU2020347154A1 (en)	2019-09-10	2022-03-03	Synthorx, Inc.	IL-2 conjugates and methods of use to treat autoimmune diseases
EP4034247A1 (de)	2019-09-25	2022-08-03	Codiak BioSciences, Inc.	Sting-agonisten mit exosomen zur behandlung von neuroimmunologischen erkrankungen
WO2021067747A1 (en)	2019-10-04	2021-04-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing ugt1a1 gene expression
EP4045062A1 (de)	2019-10-14	2022-08-24	Astrazeneca AB	Modulatoren der pnpla3-expression
EP4045652A1 (de)	2019-10-18	2022-08-24	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen eines elements der solute-carrier-familie und verwendungsverfahren dafür
JP2022553348A (ja)	2019-10-22	2022-12-22	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体成分Ｃ３ｉＲＮＡ組成物およびその使用方法
KR20220094213A (ko)	2019-11-01	2022-07-05	알닐람 파마슈티칼스 인코포레이티드	헌팅틴 (HTT) iRNA 제제 조성물 및 이의 사용 방법
EP4051796A1 (de)	2019-11-01	2022-09-07	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zum unterdrücken der dnajb1-prkaca-fusionsgenexpression
JP2022554272A (ja)	2019-11-04	2022-12-28	シンソークス，インコーポレイテッド	インターロイキン１０コンジュゲートおよびその使用
CN114981431A (zh)	2019-11-13	2022-08-30	阿尔尼拉姆医药品有限公司	用于治疗血管紧张素原(agt)相关病症的方法和组合物
US20230056569A1 (en)	2019-11-22	2023-02-23	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
MX2022006433A (es)	2019-12-13	2022-06-23	Alnylam Pharmaceuticals Inc	Composiciones de agentes de acido ribonucleico de interferencia (arni) del marco de lectura abierto 72 del cromosoma 9 humano (c9orf72) y metodos de uso de los mismos.
TW202138559A (zh)	2019-12-16	2021-10-16	美商阿尼拉製藥公司	含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法
EP4077669A1 (de)	2019-12-19	2022-10-26	F. Hoffmann-La Roche AG	Verwendung von sbds-inhibitoren zur behandlung von hepatitis-b-virus-infektionen
EP4077671A1 (de)	2019-12-19	2022-10-26	F. Hoffmann-La Roche AG	Verwendung von saraf-inhibitoren zum behandeln von hepatitis-b-virus-infektionen
JP2023506540A (ja)	2019-12-19	2023-02-16	エフ．ホフマン－ラロシュエージー．	Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用
JP2023506547A (ja)	2019-12-19	2023-02-16	エフ．ホフマン－ラロシュエージー．	Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用
EP4077667A1 (de)	2019-12-19	2022-10-26	F. Hoffmann-La Roche AG	Verwendung von sept9-inhibitoren zum behandeln von hepatitis-b-virus-infektionen
JP7288052B2 (ja)	2019-12-20	2023-06-06	エフ．ホフマン－ラロシュアーゲー	Ｓｃｎ９ａ発現を阻害するための増強されたオリゴヌクレオチド
JP2023509872A (ja)	2019-12-24	2023-03-10	エフ．ホフマン－ラロシュアーゲー	Ｈｂｖを標的とする抗ウイルス剤及び／又はｈｂｖの処置のための免疫調節剤の医薬組合せ
EP4081639A1 (de)	2019-12-24	2022-11-02	F. Hoffmann-La Roche AG	Pharmazeutische kombination eines therapeutischen oligonucleotids gegen hbv und eines tlr7-agonisten zur behandlung von hbv
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
WO2021158810A1 (en)	2020-02-05	2021-08-12	Bristol-Myers Squibb Company	Oligonucleotides for splice modulation of camk2d
WO2021163066A1 (en)	2020-02-10	2021-08-19	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing vegf-a expression
AU2021224778A1 (en)	2020-02-18	2022-09-29	Alnylam Pharmaceuticals, Inc.	Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
US20220064638A1 (en)	2020-02-28	2022-03-03	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating smn2
EP4110916A1 (de)	2020-02-28	2023-01-04	F. Hoffmann-La Roche AG	Oligonukleotide zum modulieren von cd73-exon-7-spleissen
US20230159924A1 (en)	2020-03-02	2023-05-25	Mitsubishi Tanabe Pharma Corporation	Prevention or treatment of aneurysms using mir-33b inhibitor
WO2021178607A1 (en)	2020-03-05	2021-09-10	Alnylam Pharmaceuticals, Inc.	Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
CN115461460A (zh)	2020-03-06	2022-12-09	阿尔尼拉姆医药品有限公司	用于抑制转甲状腺素蛋白(ttr)的表达的组合物和方法
CA3174725A1 (en)	2020-03-06	2021-09-10	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
WO2021184020A1 (en)	2020-03-13	2021-09-16	Codiak Biosciences, Inc.	Methods of treating neuroinflammation
WO2021184021A1 (en)	2020-03-13	2021-09-16	Codiak Biosciences, Inc.	Extracellular vesicle-aso constructs targeting pmp22
WO2021188611A1 (en)	2020-03-18	2021-09-23	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
CN116209759A (zh)	2020-03-26	2023-06-02	阿尔尼拉姆医药品有限公司	冠状病毒iRNA组合物及其使用方法
US20230190785A1 (en)	2020-03-30	2023-06-22	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajc15 gene expression
BR112022020145A2 (pt)	2020-04-06	2023-01-03	Alnylam Pharmaceuticals Inc	Composições e métodos para silenciamento da expressão de myoc
EP4133077A1 (de)	2020-04-07	2023-02-15	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
EP4133076A1 (de)	2020-04-07	2023-02-15	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen aus angiotensin-konvertierendem enzym 2 (ace2) und verfahren zur verwendung davon
KR20230008078A (ko)	2020-04-07	2023-01-13	알닐람 파마슈티칼스 인코포레이티드	Scn9a 발현을 사일런싱하기 위한 조성물 및 방법
AU2021258193A1 (en)	2020-04-21	2022-11-24	Flagship Pioneering, Inc.	Bifunctional molecules and methods of using thereof
IL297702A (en)	2020-04-27	2022-12-01	Alnylam Pharmaceuticals Inc	Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
KR20230017789A (ko)	2020-04-30	2023-02-06	알닐람 파마슈티칼스 인코포레이티드	보체 인자 B (CFB) iRNA 조성물 및 이의 사용 방법
CA3181546A1 (en)	2020-05-01	2021-11-04	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating atxn1
US20230287410A1 (en)	2020-05-11	2023-09-14	Stoke Therapeutics, Inc.	Opa1 antisense oligomers for treatment of conditions and diseases
EP4150085A1 (de)	2020-05-11	2023-03-22	Genentech, Inc.	Komplementkomponente c1r-inhibitoren zur behandlung einer neurologischen erkrankung sowie zugehörige zusammensetzungen, systeme und verfahren zur verwendung davon
JP2023525770A (ja)	2020-05-11	2023-06-19	ジェネンテック，インコーポレイテッド	神経学的疾患を処置するための補体ｃ４阻害剤および関連する組成物、ならびにそれを使用するシステムおよび方法
CN115551519A (zh)	2020-05-11	2022-12-30	基因泰克公司	用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
CN115667513A (zh)	2020-05-12	2023-01-31	田边三菱制药株式会社	用于调节Ataxin 3表达的化合物、方法和药物组合物
WO2021229036A1 (en)	2020-05-13	2021-11-18	F. Hoffmann-La Roche Ag	Oligonucleotide agonists targeting progranulin
EP4150090A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von otoflin (otof)
EP4150086A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von leucinreicher repeat-kinase 2 (lrrk2)
EP4150078A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten editierung von argininosuccinat-lyase (asl)
EP4150087A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung des gap-junction-proteins beta 2 (gjb2)
EP4150089A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von retinosin 1 (rs1)
CA3162416C (en)	2020-05-15	2023-07-04	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
EP4150076A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
EP4150077A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
EP4153746A1 (de)	2020-05-21	2023-03-29	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
JP2023526096A (ja)	2020-05-22	2023-06-20	エフ．ホフマン－ラロシュアーゲー	Ｃａｒｄ９のスプライス調節のためのオリゴヌクレオチド
US11408000B2 (en)	2020-06-03	2022-08-09	Triplet Therapeutics, Inc.	Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
EP4162047A1 (de)	2020-06-09	2023-04-12	Roche Innovation Center Copenhagen A/S	Guanosinanaloga zur verwendung in therapeutischen polynukleotiden
WO2021252557A1 (en)	2020-06-09	2021-12-16	Alnylam Pharmaceuticals, Inc.	Rnai compositions and methods of use thereof for delivery by inhalation
BR112022024420A2 (pt)	2020-06-18	2023-01-17	Alnylam Pharmaceuticals Inc	Composições de irna de xantina desidrogenase (xdh) e métodos de uso das mesmas
AU2021296848A1 (en)	2020-06-24	2023-02-09	Humabs Biomed Sa	Engineered hepatitis B virus neutralizing antibodies and uses thereof
CA3183834A1 (en)	2020-06-25	2021-12-30	Giovanni Abbadessa	Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodies
AR122731A1 (es)	2020-06-26	2022-10-05	Hoffmann La Roche	Oligonucleótidos mejorados para modular la expresión de fubp1
TW202216996A (zh)	2020-06-29	2022-05-01	美商Ionis製藥公司	調節ｐｌｐ１之化合物及方法
JPWO2022014703A1 (de)	2020-07-17	2022-01-20
WO2022018155A1 (en)	2020-07-23	2022-01-27	F. Hoffmann-La Roche Ag	Lna oligonucleotides for splice modulation of stmn2
JP2023534557A (ja)	2020-07-23	2023-08-09	エフ．ホフマン－ラロシュアーゲー	Ｒｎａ結合タンパク質部位を標的とするオリゴヌクレオチド
BR112023002034A2 (pt)	2020-08-07	2023-04-04	Ionis Pharmaceuticals Inc	Compostos e métodos para modulação de scn2a
CN116157522A (zh)	2020-08-21	2023-05-23	豪夫迈·罗氏有限公司	A1cf抑制剂用于治疗乙型肝炎病毒感染的用途
TW202227102A (zh)	2020-09-22	2022-07-16	瑞典商阿斯特捷利康公司	治療脂肪肝病之方法
WO2022066847A1 (en)	2020-09-24	2022-03-31	Alnylam Pharmaceuticals, Inc.	Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
EP4225917A1 (de)	2020-10-05	2023-08-16	Alnylam Pharmaceuticals, Inc.	G-protein-gekoppelter rezeptor-75 (gpr75)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022076596A1 (en)	2020-10-06	2022-04-14	Codiak Biosciences, Inc.	Extracellular vesicle-aso constructs targeting stat6
BR112023006024A2 (pt)	2020-10-09	2023-05-09	Synthorx Inc	Terapias de imuno-oncologia com conjugados de il-2
TW202228785A (zh)	2020-10-09	2022-08-01	美商欣爍克斯公司	使用il-2接合物及帕博利珠單抗(pembrolizumab)之免疫腫瘤學組合療法
WO2022087041A1 (en)	2020-10-21	2022-04-28	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating primary hyperoxaluria
EP4232582A1 (de)	2020-10-23	2023-08-30	Alnylam Pharmaceuticals, Inc.	Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
AU2021380809A1 (en)	2020-11-13	2023-06-22	Alnylam Pharmaceuticals, Inc.	COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2022109139A1 (en)	2020-11-18	2022-05-27	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating angiotensinogen expression
AU2021384225A1 (en)	2020-11-18	2023-07-06	Lemba Bv	Umlilo antisense transcription inhibitors
US20240002853A1 (en)	2020-11-23	2024-01-04	Alpha Anomeric Sas	Nucleic acid duplexes
US11987795B2 (en)	2020-11-24	2024-05-21	The Broad Institute, Inc.	Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11
TW202237150A (zh)	2020-12-01	2022-10-01	美商艾拉倫製藥股份有限公司	用於抑制ｈａｏ１（羥基酸氧化酶１（乙醇酸氧化酶））基因表現的方法及組成物
US20230060373A1 (en)	2020-12-03	2023-03-02	Hoffmann-La Roche Inc.	Antisense Oligonucleotides Targeting ATXN3
WO2022117745A1 (en)	2020-12-03	2022-06-09	F. Hoffmann-La Roche Ag	Antisense oligonucleotides targeting atxn3
CN116568696A (zh)	2020-12-08	2023-08-08	豪夫迈·罗氏有限公司	二硫代磷酸酯寡核苷酸的新颖合成
WO2022125490A1 (en)	2020-12-08	2022-06-16	Alnylam Pharmaceuticals, Inc.	Coagulation factor x (f10) irna compositions and methods of use thereof
GB2603454A (en)	2020-12-09	2022-08-10	Ucl Business Ltd	Novel therapeutics for the treatment of neurodegenerative disorders
WO2022133278A2 (en)	2020-12-18	2022-06-23	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating factor xii
JP2023553710A (ja)	2020-12-18	2023-12-25	エフ．ホフマン－ラロシュアーゲー	プログラニュリンを標的とするためのアンチセンスオリゴヌクレオチド
CN116670282A (zh)	2020-12-22	2023-08-29	豪夫迈·罗氏有限公司	靶向xbp1的寡核苷酸
WO2022150260A1 (en)	2021-01-05	2022-07-14	Alnylam Pharmaceuticals, Inc.	COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
TW202246500A (zh)	2021-02-02	2022-12-01	瑞士商赫孚孟拉羅股份公司	用於抑制ｒｔｅｌ１表現之增強型寡核苷酸
WO2022174101A1 (en)	2021-02-12	2022-08-18	Synthorx, Inc.	Skin cancer combination therapy with il-2 conjugates and cemiplimab
KR20230146048A (ko)	2021-02-12	2023-10-18	알닐람 파마슈티칼스 인코포레이티드	슈퍼옥사이드 디스뮤타제 1(sod1) irna 조성물 및 슈퍼옥사이드 디스뮤타제 1- (sod1-) 관련 신경퇴행성 질환을 치료하거나 예방하기 위한 이의 사용 방법
WO2022174102A1 (en)	2021-02-12	2022-08-18	Synthorx, Inc.	Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
CN117157093A (zh)	2021-02-17	2023-12-01	隆萨销售股份有限公司	细胞外囊泡-nlrp3拮抗剂
CA3207947A1 (en)	2021-02-17	2022-08-25	Aaron Noyes	Extracellular vesicle linked to a biologically active molecule via an optimized linker and an anchoring moiety
JP2024509783A (ja)	2021-02-25	2024-03-05	アルナイラムファーマシューティカルズ，インコーポレイテッド	プリオンタンパク質（ｐｒｎｐ）ｉｒｎａ組成物およびその使用方法
EP4298218A1 (de)	2021-02-26	2024-01-03	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
IL305418A (en)	2021-03-04	2023-10-01	Alnylam Pharmaceuticals Inc	Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
EP4305169A1 (de)	2021-03-12	2024-01-17	Alnylam Pharmaceuticals, Inc.	Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
CN117203336A (zh)	2021-03-29	2023-12-08	阿尔尼拉姆医药品有限公司	亨廷顿蛋白(HTT)iRNA药剂组合物以及其使用方法
JP2024519601A (ja)	2021-03-31	2024-05-20	エントラーダセラピューティクス，インコーポレイティド	環状細胞透過性ペプチド
US20240209368A1 (en)	2021-04-01	2024-06-27	Lonza Sales Ag	Extracellular vesicle compositions
WO2022212153A1 (en)	2021-04-01	2022-10-06	Alnylam Pharmaceuticals, Inc.	Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
WO2022214632A1 (en)	2021-04-07	2022-10-13	Neoplants Sas	Compositions and methods for indoor air remediation
AU2022264478A1 (en)	2021-04-26	2023-10-12	Alnylam Pharmaceuticals, Inc.	Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
JP2024519293A (ja)	2021-04-29	2024-05-10	アルナイラムファーマシューティカルズ，インコーポレイテッド	シグナル伝達兼転写活性化因子６（ＳＴＡＴ６）ｉＲＮＡ組成物およびその使用方法
WO2022230987A1 (ja)	2021-04-30	2022-11-03	田辺三菱製薬株式会社	ｍｉＲ－３３ｂ阻害物質による筋疾患の予防又は治療
EP4337263A1 (de)	2021-05-10	2024-03-20	Entrada Therapeutics, Inc.	Zusammensetzungen und verfahren zur modulation der interferon-regulatorischen faktor-5 (irf-5)-aktivität
CA3218805A1 (en)	2021-05-10	2022-11-17	Ziqing QIAN	Compositions and methods for intracellular therapeutics
WO2022240760A2 (en)	2021-05-10	2022-11-17	Entrada Therapeutics, Inc.	COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING
JP2024522068A (ja)	2021-05-18	2024-06-11	アルナイラムファーマシューティカルズ，インコーポレイテッド	ナトリウム－グルコース共輸送体２（ｓｇｌｔ２）ｉｒｎａ組成物およびその使用方法
EP4341405A1 (de)	2021-05-20	2024-03-27	Korro Bio, Inc.	Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
AU2022286925A1 (en)	2021-05-29	2023-12-21	1Globe Health Institute Llc	Short duplex dna as a novel gene silencing technology and use thereof
KR20240014532A (ko)	2021-05-29	2024-02-01	1글로브 헬스 인스티튜트 엘엘씨	신규한 유전자 침묵 기술로서의 비대칭의 짧은 듀플렉스 dna 및 이의 용도
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
WO2022256395A1 (en)	2021-06-02	2022-12-08	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2022256534A1 (en)	2021-06-03	2022-12-08	Synthorx, Inc.	Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
AR126000A1 (es)	2021-06-04	2023-08-30	Alnylam Pharmaceuticals Inc	Agentes de arni del marco de lectura abierto 72 del cromosoma 9 humano (c9orf72), composiciones y métodos de uso de los mismos
WO2022260939A2 (en)	2021-06-08	2022-12-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
AR126085A1 (es)	2021-06-08	2023-09-13	Hoffmann La Roche	Agonistas de progranulina de oligonucleótido
EP4105328A1 (de)	2021-06-15	2022-12-21	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Antisense-oligonukleotide zur prävention von nierenfunktionsstörungen, die durch endotheliale dysfunktion gefördert werden, durch unterdrückung von ephrin-b2
WO2022266414A1 (en)	2021-06-18	2022-12-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing ifnar1 expression
JP2024524291A (ja)	2021-06-23	2024-07-05	エントラーダセラピューティクス，インコーポレイティド	Ｃｕｇリピートを標的とするためのアンチセンス化合物及び方法
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
US20250034564A1 (en)	2021-06-29	2025-01-30	Korro Bio, Inc.	Methods and Compositions for ADAR-Mediated Editing
IL309296A (en)	2021-06-30	2024-02-01	Alnylam Pharmaceuticals Inc	Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
JP2024528659A (ja)	2021-07-19	2024-07-30	アルナイラムファーマシューティカルズ，インコーポレイテッド	非原発性高シュウ酸尿症疾患または障害を有するまたは発症するリスクがある対象を治療するための方法および組成物
EP4373933A1 (de)	2021-07-23	2024-05-29	Alnylam Pharmaceuticals, Inc.	Beta-catenin (ctnb1)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4377458A1 (de)	2021-07-29	2024-06-05	Alnylam Pharmaceuticals, Inc.	3-hydroxy-3-methylglutaryl-coa-reduktase (hmgcr)-irna-zusammensetzungen und verfahren zur verwendung davon
MX2024001194A (es)	2021-08-03	2024-02-27	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) de transtiretina (ttr) y sus metodos de uso.
CA3228255A1 (en)	2021-08-04	2023-02-09	Alnylam Pharmaceuticals, Inc.	Irna compositions and methods for silencing angiotensinogen (agt)
KR20240045300A (ko)	2021-08-13	2024-04-05	알닐람 파마슈티칼스 인코포레이티드	인자 XII (F12) iRNA 조성물 및 이의 사용 방법
CA3229305A1 (en)	2021-08-16	2023-02-23	Vib Vzw	Oligonucleotides for modulating synaptogyrin-3 expression
MX2024002640A (es)	2021-09-01	2024-07-19	Entrada Therapeutics Inc	Compuestos y metodos para salto de exon 44 en la distrofia muscular de duchenne.
EP4396352A2 (de)	2021-09-01	2024-07-10	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur reduzierung der dmpk-expression
WO2023044370A2 (en)	2021-09-17	2023-03-23	Alnylam Pharmaceuticals, Inc.	Irna compositions and methods for silencing complement component 3 (c3)
CN118159654A (zh)	2021-09-20	2024-06-07	阿尔尼拉姆医药品有限公司	抑制素亚基βE（INHBE）调节剂组合物及其使用方法
CN118019848A (zh)	2021-09-29	2024-05-10	豪夫迈·罗氏有限公司	Rna编辑
JP2024537775A (ja)	2021-09-30	2024-10-16	アコーオスインコーポレイテッド	Ｋｃｎｑ４関連難聴を治療するための組成物及び方法
US12042509B2 (en)	2021-10-01	2024-07-23	Adarx Pharmaceuticals, Inc.	Prekallikrein-modulating compositions and methods of use thereof
AU2022370009A1 (en)	2021-10-22	2024-05-16	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
EP4423272A2 (de)	2021-10-29	2024-09-04	Alnylam Pharmaceuticals, Inc.	Huntingtin (htt)-irna-wirkstoffzusammensetzungen und verfahren zur verwendung davon
CA3234636A1 (en)	2021-10-29	2023-05-04	Alnylam Pharmaceuticals, Inc.	Complement factor b (cfb) irna compositions and methods of use thereof
WO2023078883A1 (en)	2021-11-03	2023-05-11	F. Hoffmann-La Roche Ag	Oligonucleotides for modulating apolipoprotein e4 expression
US20250066790A1 (en)	2021-11-10	2025-02-27	University Of Rochester	Antisense oligonucleotides for modifying protein expression
EP4444881A2 (de)	2021-11-10	2024-10-16	University of Rochester	Auf gata4 abzielende therapeutika zur behandlung von herzhypertrophie
EP4430184A2 (de)	2021-11-11	2024-09-18	F. Hoffmann-La Roche AG	Pharmazeutische kombinationen zur behandlung von hbv
EP4441224A1 (de)	2021-12-03	2024-10-09	Quralis Corporation	Gapmer-antisense-oligonukleotide mit modifizierter rückgratchemie
JP2025501457A (ja)	2021-12-07	2025-01-22	エフ．ホフマン－ラロシュアーゲー	Ａｃｔｌ６ｂを標的とするアンチセンスオリゴヌクレオチド
GB202117758D0 (en)	2021-12-09	2022-01-26	Ucl Business Ltd	Therapeutics for the treatment of neurodegenerative disorders
JP2024546887A (ja)	2021-12-17	2024-12-26	ジェネンテック，インコーポレイテッド	オリゴヌクレオチドｇｂａアゴニスト
WO2023111210A1 (en)	2021-12-17	2023-06-22	F. Hoffmann-La Roche Ag	Combination of oligonucleotides for modulating rtel1 and fubp1
EP4453206A1 (de)	2021-12-20	2024-10-30	F. Hoffmann-La Roche AG	Threose-nukleinsäure-antisense-oligonukleotide und verfahren dafür
EP4452327A1 (de)	2021-12-20	2024-10-30	Synthorx, Inc.	Kopf-hals-krebskombinationstherapie mit einem il-2-konjugat und pembrolizumab
IL313660A (en)	2021-12-22	2024-08-01	Camp4 Therapeutics Corp	Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs
WO2023122750A1 (en)	2021-12-23	2023-06-29	Synthorx, Inc.	Cancer combination therapy with il-2 conjugates and cetuximab
JPWO2023127857A1 (de) *	2021-12-27	2023-07-06
WO2023141507A1 (en)	2022-01-20	2023-07-27	Genentech, Inc.	Antisense oligonucleotides for modulating tmem106b expression
WO2023141314A2 (en)	2022-01-24	2023-07-27	Alnylam Pharmaceuticals, Inc.	Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
US20240167040A1 (en)	2022-02-21	2024-05-23	Hoffmann-La Roche Inc.	Antisense oligonucleotide
AU2023234536A1 (en)	2022-03-16	2024-09-26	Empirico Inc.	Galnac compositions for improving sirna bioavailability
CN119173632A (zh)	2022-05-10	2024-12-20	豪夫迈·罗氏有限公司	靶向cfp-elk1基因间区域的反义寡核苷酸
TW202409276A (zh)	2022-05-18	2024-03-01	瑞士商赫孚孟拉羅股份公司	改良之靶向ｒｎａ結合蛋白位點的寡核苷酸
IL317425A (en)	2022-06-10	2025-02-01	Camp4 Therapeutics Corp	Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory RNAs
WO2023242324A1 (en)	2022-06-17	2023-12-21	F. Hoffmann-La Roche Ag	Antisense oligonucleotides for targeting progranulin
AU2023314808A1 (en)	2022-07-29	2025-03-20	Regeneron Pharmaceuticals, Inc.	Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024040041A1 (en)	2022-08-15	2024-02-22	Dicerna Pharmaceuticals, Inc.	Regulation of activity of rnai molecules
WO2024039776A2 (en)	2022-08-18	2024-02-22	Alnylam Pharmaceuticals, Inc.	Universal non-targeting sirna compositions and methods of use thereof
EP4332221A1 (de)	2022-08-29	2024-03-06	Roche Innovation Center Copenhagen A/S	Threose-nukleinsäure-antisense-oligonukleotide und verfahren dafür
WO2024050261A1 (en)	2022-08-29	2024-03-07	University Of Rochester	Antisense oligonucleotide-based anti-fibrotic therapeutics
AU2023337487A1 (en)	2022-09-06	2025-02-13	F. Hoffmann-La Roche Ag	Double-stranded rna molecule for administration to the eye
TW202424193A (zh)	2022-09-15	2024-06-16	美商艾拉倫製藥股份有限公司	第１３型１７β－羥基類固醇去氫酶（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物及其使用方法
US12152052B2 (en)	2022-09-23	2024-11-26	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing MECP2 expression
WO2024098061A2 (en)	2022-11-04	2024-05-10	Genkardia Inc.	Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
WO2024098002A1 (en)	2022-11-04	2024-05-10	Regeneron Pharmaceuticals, Inc.	Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
WO2024107765A2 (en)	2022-11-14	2024-05-23	Regeneron Pharmaceuticals, Inc.	Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
WO2024119145A1 (en)	2022-12-01	2024-06-06	Camp4 Therapeutics Corporation	Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2024124041A1 (en)	2022-12-07	2024-06-13	Advanced Cell Diagnostics, Inc.	Multiplexed detection of nucleic acid targets
WO2024126654A1 (en)	2022-12-14	2024-06-20	F. Hoffmann-La Roche Ag	Antisense oligonucleotides targeting actl6b
WO2024136899A1 (en)	2022-12-21	2024-06-27	Synthorx, Inc.	Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
WO2024160756A1 (en)	2023-01-30	2024-08-08	Vib Vzw	Suppressors of tauopathies
TW202449152A (zh)	2023-02-09	2024-12-16	美商艾拉倫製藥股份有限公司	Ｒｅｖｅｒｓｉｒ分子及其使用方法
WO2024175588A1 (en)	2023-02-21	2024-08-29	Vib Vzw	Oligonucleotides for modulating synaptogyrin-3 expression
WO2024175586A2 (en)	2023-02-21	2024-08-29	Vib Vzw	Inhibitors of synaptogyrin-3 expression
WO2024178172A1 (en)	2023-02-23	2024-08-29	University Of Rochester	Agents and methods for making closed-end dna thread molecules
WO2024196937A1 (en)	2023-03-20	2024-09-26	Synthorx, Inc.	Cancer therapy with il-2 peg conjugates
US20240358820A1 (en)	2023-03-23	2024-10-31	Carbon Biosciences, Inc.	Protoparvovirus compositions comprising a protoparvovirus variant vp1 capsid polypeptide and related methods
WO2024196965A1 (en)	2023-03-23	2024-09-26	Carbon Biosciences, Inc.	Parvovirus compositions and related methods for gene therapy
TW202448484A (zh)	2023-04-20	2024-12-16	美商雅迪克斯製藥公司	Ｍａｐｔ調節組合物及其使用方法
WO2024220746A2 (en)	2023-04-21	2024-10-24	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting fatty acid synthase and related methods
WO2024227047A2 (en)	2023-04-28	2024-10-31	Beam Therapeutics Inc.	Modified guide rna
WO2024227765A2 (en)	2023-05-04	2024-11-07	F. Hoffmann-La Roche Ag	Oligonucleotides capable of upregulating glucocerebrosidase expression
WO2024233864A2 (en)	2023-05-10	2024-11-14	Dicerna Pharmaceuticals, Inc.	Galnac-conjugated rnai oligonucleotides
WO2024238396A1 (en)	2023-05-12	2024-11-21	Adarx Pharmaceuticals, Inc.	Nmda ligand conjugated compounds and uses thereof
WO2024249328A2 (en)	2023-05-26	2024-12-05	Adarx Pharmaceuticals, Inc.	Sod1-modulating compositions and methods of use thereof
US20250034576A1 (en)	2023-06-16	2025-01-30	Hoffmann-La Roche Inc.	Double Stranded Oligonucleotide For Modulating JAK1 Expression
WO2024263694A1 (en)	2023-06-20	2024-12-26	Adarx Pharmaceuticals, Inc.	Lrrk2-modulating compositions and methods of use thereof
WO2025015335A1 (en)	2023-07-13	2025-01-16	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
WO2025024334A1 (en)	2023-07-21	2025-01-30	Marrow Therapeutics, Inc.	Hematopoietic cell targeting conjugates and related methods
US20250092426A1 (en)	2023-07-25	2025-03-20	Flagship Pioneering Innovations Vii, Llc	Cas endonucleases and related methods
WO2025024493A1 (en)	2023-07-25	2025-01-30	Flagship Pioneering Innovations Vii, Llc	Cas endonucleases and related methods
WO2025034422A1 (en)	2023-08-04	2025-02-13	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating ctnnb1-associated disorders
WO2025054459A1 (en)	2023-09-08	2025-03-13	Dicerna Pharmaceuticals, Inc.	Rnai oligonucleotide conjugates

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3687808A (en)	1969-08-14	1972-08-29	Univ Leland Stanford Junior	Synthetic polynucleotides
US5132418A (en)	1980-02-29	1992-07-21	University Patents, Inc.	Process for preparing polynucleotides
US4458066A (en)	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
US4500707A (en) *	1980-02-29	1985-02-19	University Patents, Inc.	Nucleosides useful in the preparation of polynucleotides
US4469863A (en)	1980-11-12	1984-09-04	Ts O Paul O P	Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4668777A (en)	1981-03-27	1987-05-26	University Patents, Inc.	Phosphoramidite nucleoside compounds
US4973679A (en)	1981-03-27	1990-11-27	University Patents, Inc.	Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en)	1981-03-27	1983-11-15	University Patents, Inc.	Phosphoramidite compounds and processes
US5023243A (en)	1981-10-23	1991-06-11	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and method of making same
US4476301A (en)	1982-04-29	1984-10-09	Centre National De La Recherche Scientifique	Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
USRE34069E (en) *	1983-08-18	1992-09-15	Biosyntech Gmbh	Process for the preparation of oligonucleotides
DE3329892A1 (de) *	1983-08-18	1985-03-07	Köster, Hubert, Prof. Dr., 2000 Hamburg	Verfahren zur herstellung von oligonucleotiden
US5118800A (en) *	1983-12-20	1992-06-02	California Institute Of Technology	Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5550111A (en) *	1984-07-11	1996-08-27	Temple University-Of The Commonwealth System Of Higher Education	Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (fr) *	1984-07-19	1989-02-17	Centre Nat Rech Scient	Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5367066A (en)	1984-10-16	1994-11-22	Chiron Corporation	Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr)	1985-01-08	1987-04-03	Pasteur Institut	Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5166315A (en)	1989-12-20	1992-11-24	Anti-Gene Development Group	Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en)	1985-03-15	1993-02-09	Anti-Gene Deveopment Group	Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5235033A (en)	1985-03-15	1993-08-10	Anti-Gene Development Group	Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) *	1985-03-15	1991-07-23	Anti-Gene Development Group	Uncharged morpholino-based polymers having achiral intersubunit linkages
US5405938A (en)	1989-12-20	1995-04-11	Anti-Gene Development Group	Sequence-specific binding polymers for duplex nucleic acids
DE3788914T2 (de) *	1986-09-08	1994-08-25	Ajinomoto Kk	Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere.
US5264423A (en)	1987-03-25	1993-11-23	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en)	1987-03-25	1994-01-04	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
JP2828642B2 (ja)	1987-06-24	1998-11-25	ハワードフローレイインスティテュトオブイクスペリメンタルフィジオロジーアンドメディシン	ヌクレオシド誘導体
US4924624A (en)	1987-10-22	1990-05-15	Temple University-Of The Commonwealth System Of Higher Education	2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en) *	1987-10-22	1993-02-23	Temple University Of The Commonwealth System Of Higher Education	Encapsulated 2',5'-phosphorothioate oligoadenylates
DE3855864T2 (de)	1987-11-30	1997-09-25	Univ Iowa Res Found	Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
US5403711A (en)	1987-11-30	1995-04-04	University Of Iowa Research Foundation	Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
WO1989009221A1 (en)	1988-03-25	1989-10-05	University Of Virginia Alumni Patents Foundation	Oligonucleotide n-alkylphosphoramidates
US5278302A (en) *	1988-05-26	1994-01-11	University Patents, Inc.	Polynucleotide phosphorodithioates
US5216141A (en)	1988-06-06	1993-06-01	Benner Steven A	Oligonucleotide analogs containing sulfur linkages
US5175273A (en)	1988-07-01	1992-12-29	Genentech, Inc.	Nucleic acid intercalating agents
US5194599A (en)	1988-09-23	1993-03-16	Gilead Sciences, Inc.	Hydrogen phosphonodithioate compositions
JP2863922B2 (ja)	1988-11-28	1999-03-03	マツダ株式会社	後輪操舵車両の後輪懸架装置
US5256775A (en)	1989-06-05	1993-10-26	Gilead Sciences, Inc.	Exonuclease-resistant oligonucleotides
US5134066A (en) *	1989-08-29	1992-07-28	Monsanto Company	Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en)	1989-09-15	1997-01-07	Southern Research Institute	2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5721218A (en)	1989-10-23	1998-02-24	Gilead Sciences, Inc.	Oligonucleotides with inverted polarity
US5399676A (en) *	1989-10-23	1995-03-21	Gilead Sciences	Oligonucleotides with inverted polarity
US5264564A (en)	1989-10-24	1993-11-23	Gilead Sciences	Oligonucleotide analogs with novel linkages
US5264562A (en)	1989-10-24	1993-11-23	Gilead Sciences, Inc.	Oligonucleotide analogs with novel linkages
DK0497875T3 (da)	1989-10-24	2000-07-03	Gilead Sciences Inc	2'-modificerede oligonukleotider
US5177198A (en)	1989-11-30	1993-01-05	University Of N.C. At Chapel Hill	Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en)	1989-12-20	1992-07-14	Boron Bilogicals, Inc.	Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5587361A (en)	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5646265A (en)	1990-01-11	1997-07-08	Isis Pharmceuticals, Inc.	Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5681941A (en)	1990-01-11	1997-10-28	Isis Pharmaceuticals, Inc.	Substituted purines and oligonucleotide cross-linking
US5459255A (en)	1990-01-11	1995-10-17	Isis Pharmaceuticals, Inc.	N-2 substituted purines
US5670633A (en)	1990-01-11	1997-09-23	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides that detect and modulate gene expression
US5623065A (en)	1990-08-13	1997-04-22	Isis Pharmaceuticals, Inc.	Gapped 2' modified oligonucleotides
US5587470A (en)	1990-01-11	1996-12-24	Isis Pharmaceuticals, Inc.	3-deazapurines
US5220007A (en)	1990-02-15	1993-06-15	The Worcester Foundation For Experimental Biology	Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en)	1990-02-15	1992-09-22	The Worcester Foundation For Experimental Biology	Method of site-specific alteration of rna and production of encoded polypeptides
US5321131A (en) *	1990-03-08	1994-06-14	Hybridon, Inc.	Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en)	1990-04-10	1995-11-28	The Dupont Merck Pharmaceutical Company	Oligonucleotide analogs with sulfamate linkages
GB9009980D0 (en)	1990-05-03	1990-06-27	Amersham Int Plc	Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
DE69032425T2 (de)	1990-05-11	1998-11-26	Microprobe Corp., Bothell, Wash.	Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden
US5677437A (en)	1990-07-27	1997-10-14	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
US5223618A (en)	1990-08-13	1993-06-29	Isis Pharmaceuticals, Inc.	4'-desmethyl nucleoside analog compounds
US5378825A (en)	1990-07-27	1995-01-03	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogs
US5610289A (en)	1990-07-27	1997-03-11	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogues
US5618704A (en) *	1990-07-27	1997-04-08	Isis Pharmacueticals, Inc.	Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5541307A (en)	1990-07-27	1996-07-30	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5623070A (en)	1990-07-27	1997-04-22	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
US5489677A (en) *	1990-07-27	1996-02-06	Isis Pharmaceuticals, Inc.	Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5608046A (en)	1990-07-27	1997-03-04	Isis Pharmaceuticals, Inc.	Conjugated 4'-desmethyl nucleoside analog compounds
US5386023A (en) *	1990-07-27	1995-01-31	Isis Pharmaceuticals	Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5602240A (en)	1990-07-27	1997-02-11	Ciba Geigy Ag.	Backbone modified oligonucleotide analogs
DE69126530T2 (de) *	1990-07-27	1998-02-05	Isis Pharmaceutical, Inc., Carlsbad, Calif.	Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren
HU217036B (hu)	1990-08-03	1999-11-29	Sanofi	Eljárás génexpresszió gátlására alkalmas vegyületek előállítására
US5177196A (en) *	1990-08-16	1993-01-05	Microprobe Corporation	Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5214134A (en)	1990-09-12	1993-05-25	Sterling Winthrop Inc.	Process of linking nucleosides with a siloxane bridge
US5561225A (en)	1990-09-19	1996-10-01	Southern Research Institute	Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
WO1992005186A1 (en) *	1990-09-20	1992-04-02	Gilead Sciences	Modified internucleoside linkages
US5432272A (en) *	1990-10-09	1995-07-11	Benner; Steven A.	Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5672697A (en)	1991-02-08	1997-09-30	Gilead Sciences, Inc.	Nucleoside 5'-methylene phosphonates
US5571799A (en)	1991-08-12	1996-11-05	Basco, Ltd.	(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
DE59208572D1 (de)	1991-10-17	1997-07-10	Ciba Geigy Ag	Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5594121A (en) *	1991-11-07	1997-01-14	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified purines
TW393513B (en)	1991-11-26	2000-06-11	Isis Pharmaceuticals Inc	Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en)	1991-11-26	1996-01-16	Gilead Sciences, Inc.	Oligonucleotides containing 5-propynyl pyrimidines
EP0637965B1 (de)	1991-11-26	2002-10-16	Isis Pharmaceuticals, Inc.	Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen
US5792608A (en) *	1991-12-12	1998-08-11	Gilead Sciences, Inc.	Nuclease stable and binding competent oligomers and methods for their use
US5359044A (en)	1991-12-13	1994-10-25	Isis Pharmaceuticals	Cyclobutyl oligonucleotide surrogates
US5700922A (en)	1991-12-24	1997-12-23	Isis Pharmaceuticals, Inc.	PNA-DNA-PNA chimeric macromolecules
FR2687679B1 (fr) *	1992-02-05	1994-10-28	Centre Nat Rech Scient	Oligothionucleotides.
JPH07504900A (ja) *	1992-03-12	1995-06-01	テンプル　ユニバーシティ−オブ　ザ　コモンウェルス　システム　オブ　ハイヤーエデュケーション	二重作用の２′，５′−オリゴアデニレート抗ウィルス誘導体およびその使用
US5633360A (en) *	1992-04-14	1997-05-27	Gilead Sciences, Inc.	Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) *	1992-06-01	1995-07-18	Gilead Sciences, Inc.	Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
NL9300058A (nl)	1992-06-18	1994-01-17	Stichting Rega V Z W	1,5-anhydrohexitol nucleoside analoga en farmaceutisch gebruik daarvan.
EP0577558A2 (de)	1992-07-01	1994-01-05	Ciba-Geigy Ag	Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
US5652355A (en) *	1992-07-23	1997-07-29	Worcester Foundation For Experimental Biology	Hybrid oligonucleotide phosphorothioates
JPH08502723A (ja)	1992-07-27	1996-03-26	ハイブライドンインコーポレイテッド	オリゴヌクレオチド・アルキルホスホノチオエート
DE69400208T2 (de)	1993-01-25	1996-11-28	Hybridon Inc	Olionukleotidalkylphosphonate und -phosphonothioate
US5476925A (en)	1993-02-01	1995-12-19	Northwestern University	Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en)	1993-03-06	1993-04-21	Ciba Geigy Ag	Chemical compounds
GB9304620D0 (en)	1993-03-06	1993-04-21	Ciba Geigy Ag	Compounds
DE69404289T2 (de)	1993-03-30	1998-02-19	Sanofi Sa	Acyclische nucleosid analoge und sie enthaltende oligonucleotidsequenzen
CA2159629A1 (en)	1993-03-31	1994-10-13	Sanofi	Oligonucleotides with amide linkages replacing phosphodiester linkages
DE4311944A1 (de) *	1993-04-10	1994-10-13	Degussa	Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
US5502177A (en)	1993-09-17	1996-03-26	Gilead Sciences, Inc.	Pyrimidine derivatives for labeled binding partners
US5457187A (en)	1993-12-08	1995-10-10	Board Of Regents University Of Nebraska	Oligonucleotides containing 5-fluorouracil
US5446137B1 (en)	1993-12-09	1998-10-06	Behringwerke Ag	Oligonucleotides containing 4'-substituted nucleotides
ES2149962T3 (es)	1993-12-09	2000-11-16	Univ Jefferson	Compuestos y metodos para mutaciones dirigidas al sitio en celulas eucarioticas.
US5519134A (en) *	1994-01-11	1996-05-21	Isis Pharmaceuticals, Inc.	Pyrrolidine-containing monomers and oligomers
US5596091A (en)	1994-03-18	1997-01-21	The Regents Of The University Of California	Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en)	1994-03-29	1997-05-06	Ribozyme Pharmaceuticals, Inc.	2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en)	1994-03-31	1997-04-29	Amgen Inc.	Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5646269A (en)	1994-04-28	1997-07-08	Gilead Sciences, Inc.	Method for oligonucleotide analog synthesis
US5525711A (en)	1994-05-18	1996-06-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pteridine nucleotide analogs as fluorescent DNA probes
US5597909A (en)	1994-08-25	1997-01-28	Chiron Corporation	Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5792747A (en)	1995-01-24	1998-08-11	The Administrators Of The Tulane Educational Fund	Highly potent agonists of growth hormone releasing hormone
US5652356A (en)	1995-08-17	1997-07-29	Hybridon, Inc.	Inverted chimeric and hybrid oligonucleotides
US6043060A (en)	1996-11-18	2000-03-28	Imanishi; Takeshi	Nucleotide analogues
JP3756313B2 (ja)	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) *	1997-03-07	2004-08-03	Takeshi Imanishi	Bicyclonucleoside and oligonucleotide analogue
DE69829760T3 (de)	1997-09-12	2016-04-14	Exiqon A/S	Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
US6794499B2 (en)	1997-09-12	2004-09-21	Exiqon A/S	Oligonucleotide analogues
US6043352A (en) *	1998-08-07	2000-03-28	Isis Pharmaceuticals, Inc.	2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
KR100573231B1 (ko)	1999-02-12	2006-04-24	상꾜 가부시키가이샤	신규 뉴클레오시드 및 올리고뉴클레오티드 유사체
US6436640B1 (en)	1999-03-18	2002-08-20	Exiqon A/S	Use of LNA in mass spectrometry
US7084125B2 (en)	1999-03-18	2006-08-01	Exiqon A/S	Xylo-LNA analogues
NZ514348A (en)	1999-05-04	2004-05-28	Exiqon As	L-ribo-LNA analogues
JP4151751B2 (ja)	1999-07-22	2008-09-17	第一三共株式会社	新規ビシクロヌクレオシド類縁体
AU2001282522A1 (en) *	2000-08-29	2002-03-13	Takeshi Imanishi	Novel nucleoside analogs and oligonucleotide derivatives containing these analogs
US6426220B1 (en)	2000-10-30	2002-07-30	Isis Pharmaceuticals, Inc.	Antisense modulation of calreticulin expression
WO2003020739A2 (en)	2001-09-04	2003-03-13	Exiqon A/S	Novel lna compositions and uses thereof
JP3712374B2 (ja) *	2001-12-06	2005-11-02	富士写真フイルム株式会社	小型磁気ディスクカートリッジ
CN100344963C (zh)	2002-01-18	2007-10-24	爱科来株式会社	具备温度检测部的分析装置
US7569575B2 (en)	2002-05-08	2009-08-04	Santaris Pharma A/S	Synthesis of locked nucleic acid derivatives
US20040219565A1 (en)	2002-10-21	2004-11-04	Sakari Kauppinen	Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US7456393B2 (en)	2003-04-10	2008-11-25	Ge Homeland Protection, Inc.	Device for testing surfaces of articles for traces of explosives and/or drugs
EP1765415A4 (de)	2004-06-03	2010-03-24	Isis Pharmaceuticals Inc	Oligomere verbindungen zur erleichterung der risc-beladung
CA2640171C (en) *	2006-01-27	2014-10-28	Isis Pharmaceuticals, Inc.	6-modified bicyclic nucleic acid analogs
US8935416B2 (en)	2006-04-21	2015-01-13	Fortinet, Inc.	Method, apparatus, signals and medium for enforcing compliance with a policy on a client computer
US9400902B2 (en)	2012-05-22	2016-07-26	Trimble Navigation Limited	Multi-modal entity tracking and display

2007
- 2007-01-27 CA CA2640171A patent/CA2640171C/en active Active
- 2007-01-27 AU AU2007211080A patent/AU2007211080B9/en active Active
- 2007-01-27 ES ES10176867.9T patent/ES2516815T3/es active Active
- 2007-01-27 US US11/627,964 patent/US7399845B2/en active Active
- 2007-01-27 PL PL07762892T patent/PL1984381T3/pl unknown
- 2007-01-27 KR KR1020137007796A patent/KR20130042043A/ko not_active Application Discontinuation
- 2007-01-27 CN CN201210111246.7A patent/CN102766630B/zh active Active
- 2007-01-27 PL PL10176867T patent/PL2314594T3/pl unknown
- 2007-01-27 CN CN201210112347.6A patent/CN102908630B/zh active Active
- 2007-01-27 DE DE602007009487T patent/DE602007009487D1/de active Active
- 2007-01-27 JP JP2008552604A patent/JP5342881B2/ja active Active
- 2007-01-27 WO PCT/US2007/061183 patent/WO2007090071A2/en active Application Filing
- 2007-01-27 DK DK07762892.3T patent/DK1984381T3/da active
- 2007-01-27 DK DK10176867.9T patent/DK2314594T3/da active
- 2007-01-27 EP EP10179781.9A patent/EP2332951A3/de not_active Withdrawn
- 2007-01-27 EP EP10176867.9A patent/EP2314594B1/de active Active
- 2007-01-27 AT AT07762892T patent/ATE482965T1/de active
- 2007-01-27 KR KR1020087020907A patent/KR101304071B1/ko active IP Right Grant
- 2007-01-27 EP EP07762892A patent/EP1984381B1/de active Active
2008
- 2008-05-29 US US12/129,154 patent/US7741457B2/en active Active
2010
- 2010-05-05 US US12/774,527 patent/US8022193B2/en active Active
2013
- 2013-01-31 JP JP2013017584A patent/JP2013147498A/ja active Pending

Also Published As

Publication number	Publication date
JP5342881B2 (ja)	2013-11-13
DE602007009487D1 (de)	2010-11-11
CN102908630B (zh)	2014-11-19
AU2007211080A1 (en)	2007-08-09
CN102766630B (zh)	2014-05-07
EP2314594B1 (de)	2014-07-23
US20100216979A1 (en)	2010-08-26
CN102908630A (zh)	2013-02-06
EP1984381A2 (de)	2008-10-29
US20090012281A1 (en)	2009-01-08
AU2007211080B9 (en)	2012-05-03
PL1984381T3 (pl)	2011-03-31
KR20130042043A (ko)	2013-04-25
CN102766630A (zh)	2012-11-07
JP2009524695A (ja)	2009-07-02
EP2314594A1 (de)	2011-04-27
WO2007090071A3 (en)	2008-01-24
EP1984381B1 (de)	2010-09-29
WO2007090071A2 (en)	2007-08-09
EP2332951A3 (de)	2014-08-13
DK1984381T3 (da)	2010-11-01
US7399845B2 (en)	2008-07-15
CA2640171A1 (en)	2007-08-09
KR101304071B1 (ko)	2013-09-06
CA2640171C (en)	2014-10-28
EP2332951A2 (de)	2011-06-15
US7741457B2 (en)	2010-06-22
ES2516815T3 (es)	2014-10-31
JP2013147498A (ja)	2013-08-01
DK2314594T3 (da)	2014-10-27
US20070249049A1 (en)	2007-10-25
AU2007211080B2 (en)	2012-04-12
KR20080088662A (ko)	2008-10-02
US8022193B2 (en)	2011-09-20
PL2314594T3 (pl)	2014-12-31

Publication	Publication Date	Title
ATE482965T1 (de)	2010-10-15	6-modifizierte bicyclische nukleinsäureanaloga
CA2651453C (en)	2014-10-14	5'-modified bicyclic nucleic acid analogs
WO2011017521A3 (en)	2011-05-12	Bicyclic cyclohexose nucleic acid analogs
ATE502038T1 (de)	2011-04-15	Azyklische amininhibitoren von nukleosidphosphorylasen und hydrolasen
CY2016052I2 (el)	2017-07-12	Τροποποιημενα φθοριομενα αναλογα νουκλεοζιδιων
HK1146410A1 (en)	2011-06-03	2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors
EP2155771A4 (de)	2012-09-05	Azidopurin-nukleoside zur behandlung von virusinfektionen
EP1994182A4 (de)	2013-11-13	Abgleit-nucleobase-analoga
EP1804812A4 (de)	2009-09-02	Fluorierte pyrrolo[2,3-d]pyrimidin-nukleoside zur behandlung rna-abhängiger rna-virusinfektionen
DK1818057T3 (da)	2010-07-19	Stabile farmaceutiske sammensætninger af montelukast-natrium
EP1937683A4 (de)	2010-08-25	Verfahren für 1h-imidazo[4,5-c]pyridine und analoga davon
WO2008089105A3 (en)	2008-09-12	Antiviral nucleoside analogs
ATE398455T1 (de)	2008-07-15	Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
EP1773355A4 (de)	2009-08-12	Nukleosid-aryl-phosporamidate zur behandlung von rna-abhängiger rna-viralinfektion
WO2007002204A3 (en)	2009-04-09	Pyrosequencing methods and related compostions
FR2883877B1 (fr)	2008-10-10	Procede de preparation de compositions de diester(s) de dianhydrohexitol
ATE533774T1 (de)	2011-12-15	Neuartige nukleosidanaloge zur behandlung von virusinfektionen
ITMI20050705A1 (it)	2006-10-21	Processo per la preparazione di dispersori di fluoropolimeri
ITMI20050247A1 (it)	2006-08-19	Processo per la preparazione di montelukast
DK1940353T3 (da)	2011-01-24	Fotostabil farmaceutisk sammensætning indeholdende brivudin til behandling af herpetisk keratitis
DE502006008973D1 (de)	2011-04-14	Verfahren zur Herstellung von Methylchlorsilanen
DE502006001333D1 (de)	2008-09-25	Verfahren zur herstellung von aminoalkylsilanen
ITMI20052464A1 (it)	2007-06-23	Procedimento per la preparazi9one di norelgestromin norelgestromina
WO2008097341A3 (en)	2008-10-30	Antiviral compounds and use thereof
ITMI20042402A1 (it)	2005-03-16	Processo per la preparazione di n,n-dimetil-n'-feniluree

Legal Events

Date	Code	Title	Description
2011-04-15	UEP	Publication of translation of european patent specification	Ref document number: 1984381 Country of ref document: EP

Date

Code

Title

Description

2011-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1984381

Country of ref document: EP